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ABSTRACT 
Charcot Marie Tooth disease (CMT) represents the most common inheritable peripheral 
group of motor and sensory disorders; affecting 1 in 2500 people worldwide. Individuals 
with CMT experience slow progressing weakness of the muscle, atrophy, mild loss of 
motor coordination and in some cases loss of sensory function in the hands and feet 
which could ultimately affect mobility. Dynein is an essential molecular motor that 
functions to transport cargos in all cells. A point mutation in the dynein heavy chain was 
discovered to cause CMT disease in humans, specifically CMT type 2O. We generated a 
knock-in mouse model bearing the same mutation(H304R) in the dynein heavy chain to 
study the disease. We utilized behavioral assays to determine whether our mutant mice 
had a phenotype linked to CMT disease. The mutant mice had motor coordination defects 
and reduced muscle strength compared to normal mice. To better understand the disease 
pathway, we obtained homozygous mutants from a heterozygous cross, and the 
homozygotes show even more severe deficits compared to heterozygotes. They also 
developed an abnormal gait which separates them from heterozygous mice. In view of the 
locomotor deficits observed in mutants, we examined the neuromuscular junction (NMJ) 
for possible impairments. We identified defects in innervation at the later stages of the 
study and abnormal NMJ architecture in the muscle as well. The dysmorphology of the 
NMJ was again worse in the homozygous mutants with reduced complexity and 
denervation at all the timepoints assessed. Our homozygous dynein mutants can live up to 
two years and therefore make the design of longitudinal studies possible.   
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Altogether, this mouse model provides dynein researchers an opportunity to work 
towards establishing the link between dynein mutations, dynein dysfunction and the onset 
and progression of disease. 
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CHAPTER 1:INTRODUCTION 
1.1 Cytoplasmic Dynein 
Intracellular transport is at the heart of the maintenance of function and structure in the 
eukaryotic cell. Cytoskeletal based molecular motors therefore play essential roles in the 
cell since they transport various cargoes from one part of the cell to the other.  
Cytoplasmic dynein is a 1.6 Mega Dalton motor protein that transports cargo retrogradely 
on microtubule tracks. Dynein is important in mitosis and the transport of intracellular 
cargoes such as mRNA-protein complexes, viruses and other organelles towards the 
center of the cell (Bhabha et al, 2016). 
Dynein belongs to the AAA+ (ATPases Associated with various cellular Activities) 
family of proteins (Neuwald, 1999). This sets it apart from the other molecular motors 
kinesin and myosin which are part of the G-protein family (Vale and Milligan, 2000). 
Myosin functions in the muscle and moves on actin tracks, but dynein and kinesin move 
along microtubules transporting cargo. There are over 15 kinesins which function as plus 
and minus-ended motors, whereas cytoplasmic dynein is solely a minus-end directed 
cargo. Dynein consists of 4 types of subunits namely the heavy chains, intermediate 
chains, light intermediate chains and light chains (Figure1A).  The heavy chain is the 
largest subunit with a molecular weight of approximately 500kDa. There are two heavy 
chains per molecule, and each contains the ATPase domains at the C-terminal end 
responsible for mechanical force for movement.   
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Figure 1 The Structure of Dynein and Dynactin 
A) The 4 subunits of dynein as well as the functional sites required for normal activity in 
cells B) The major activator of dynein, with its subunits and some of the functional 
domains 
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There are 6 AAA+ domains in the dynein heavy chain and AAA1 is believed to be where 
most of the ATP hydrolysis occurs (Gibbons et al,1987). AAA3 and AA4 are also able to 
cleave ATP and further experiments show that when nucleotide binding is interrupted in 
these domains there is a corresponding change in dynein motility (Cho et al, 2008; 
DeWittt et al, 2015; Silvanovich et al, 2003). AAA5 and AAA6 do not bind nucleotides 
but help the motor detach from microtubules via a coupled rotational movement (Schmidt 
et al, 2014).  Cytoplasmic dynein binds microtubules with a 15nm coiled coil stalk 
projecting from AAA4. The stalk has a specialized α-helical domain for microtubule 
binding (Carter et al, 2008; Carter et al, 2011). The tail segment or N-terminal region of 
the dynein heavy chain dimerizes and provides the sites for attachment of the other 
dynein subunits namely the intermediate chain, light intermediate chain and light chains. 
The intermediate chain is the site of attachment of important dynein regulators such as 
Nudel/NudE, Lis1 and dynactin (McKenney et al, 2011; Nyarko et al, 2012). The light 
chains are the sites of cargo attachment and are also the smallest of the dynein subunits. 
Rp3 (13kD), Tctex-1 (12.4kD), LC8 (10.3kD) and LC7/robl (11kD) (King et al, 1998. 
King et al,2002). siRNA depletion experiments involving some light chains points to a 
role in endosome trafficking and mitosis (Palmer et al, 2009.)  
Dynein is ubiquitously expressed in all cells and is critical during development. For 
instance, during mitosis it generates the force that is required to organize the 
microtubules and position the spindles. Dynein transports checkpoint proteins that play a 
role in regulating mitosis (Howell et al, 2001 & Varma et al, 2008). Dynein function 
requires dynactin, an adaptor found to make the motor protein processive (King and 
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Schroer,2000). Dynactin has a size of about 1MDa and is made up of 11 subunits with 
the largest being p150 (Figure 1B). Dynactin interacts with dynein via its p150 subunit, 
which bears a CAP-Gly (cytoskeleton-associated protein glycine-rich) domain to attach 
to microtubules thereby ensuring that dynein does not fall off the microtubules. Dynactin 
is needed in most of the dynein cellular functions; there is some evidence for the 
attachment of cargos to both dynein and dynactin (Allan, 2011). The intermediate chain 
of dynein and p150 of dynactin interact directly to ensure the proper microtubule 
arrangement within cells and architecture of the centrosome (King et al, 2003).  The Arp1 
filament of dynactin associates with βIII spectrin, a surface protein on Golgi and some 
membranes which might implicate a role in the movement of vesicles. Interactions have 
also been reported with COPII vesicle protein SEC23 and a Rab7 GTPase effector, RILP 
(Rab-interacting lysosomal protein) (Kardon & Vale, 2009). 
Apart from dynactin, there are other accessory proteins that are necessary for proper 
dynein function, these include LIS1, NudE/Nudel, BicD and ZW10. Mutations in LIS1 
have been implicated in Lissencephaly or smooth brain; a neurological disorder affecting 
development with the hallmark features of a smooth cerebrum, intellectual defects and 
seizures. The disorder arises from impairments in proliferation of progenitor cells, 
nucleokinesis and neuronal migration (Reiner, 2013).  Lis1 is the only known dynein 
regulator which is able to interact directly with the motor domain, specifically AAA3 and 
AAA4, suggesting a more significant effect on dynein’s motion and function as well 
(Huang et al, 2012. Toropova et al, 2014). More evidence of Lis1 involvement in 
neurodevelopment is observed in its association with Nudel and NudE. These 
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homologous proteins are essential for mitosis and neurodevelopment. (Bradshaw et al, 
2013). NudE recruits Lis1 to dynein and their added effect allows dynein to generate the 
drag force to move heavy cargo like the nucleus. Nudel on the other hand may work 
conversely by preventing the motor protein from attaching to microtubules (McKenney et 
al, 2010).  The Axon initial segment (AIS) is the location where nerve impulses are 
initiated, it also serves as a neuronal barrier that helps differentiate dendritic identity from 
axonal identity during neuronal development (Palay et al,1968; Rasband, 2010). The 
maintenance of a peculiar identity by either the axon or dendrite is found to be dependent 
partly on the activity of motor proteins. Nudel has been shown to associate with an 
essential organizer of the AIS, Ankyrin G. A Lis1- mediated pathway leads to the 
activation of dynein and transport of cargo out of the AIS (Kuijpers et al,2016). 
ZW10 is a part of a complex that attaches to the kinetochore and binds it to microtubules. 
ZW10 is responsible for targeting dynactin and dynein to the kinetochore (Stehman et al, 
2007, Starr et al, 1998). Although it is directly bound to the p50 protein of dynactin, 
ablation of ZW10 results in the loss of dynein at kinetochores, indicating that ZW10 
perhaps indirectly stabilizes dynein at the kinetochores. BicD was discovered in 
Drosophila as a factor that links dynein to some of its cargoes. Structural studies showed 
that the CC1 and CC2 domains at the N-terminal of BicD bind to dynein and dynactin, 
whereas the CC3 domain might specifically bind to cargoes such as Rab6 and some 
pathogen-linked proteins (Liu et al, 2013). BicD like some other linker proteins are being 
appreciated more and more as more than just cargo adapters but regulators of dynein 
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motility. For instance, there are suggestions that BicD could influence the processivity of 
dynein (Schlager et al, 2014). 
1.2 Dynein Heavy Chain Mutations & Disease Models 
Axonal transport is particularly vital to the functions of neurons given the distance that 
separates the soma  from the synaptic region at the tip of the axon and dendritic 
compartments. Transport and timely delivery of cellular cargo to the right targets 
prevents the disruption of neuronal functions that could possibly result in disease.  
Our initial understanding of dynein structure and functions have come from experiments 
in cell culture targeting dynein transport mechanisms and their effect on the so-called 
housekeeping roles of dynein in the cell. Previous researchers showed that dynein null 
mice die at the embryonic stage suggesting the need for dynein in development (Harada 
et al, 1998). This broadly established dynein as an essential factor that supports life 
making it even more worth studying. Other studies brought insights into more of the roles 
of dynein, such as the trafficking of endosomes and lysosomes, organelles and mitosis 
(Moore and Cooper, 2010). Genetic manipulations in yeast and fungi have been 
invaluable in shedding more light on how dynein mutations might result in disease 
(Sivagurunathan, S. et al. 2012, Qiu et al, 2013). Some of the mutations disrupt axonal 
transport, which is a well-known mechanism in the occurrence of neurodegenerative 
diseases like Parkinson’s, Alzheimer’s and Huntingtin’s (Liu et al, 2012; Lloyd, 2012; 
Vicario Orri et al, 2015; Hoang et al,2017). Some of these mutations affect not only the 
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motor proteins themselves and but accessory proteins that aid them perform multiple 
roles. Additionally, the cytoskeleton, which constitute the tracks on which the motors 
travel, can also be targets of mutations that in turn hinder molecular motors and 
eventually result in disease (Poirier et al,2013; Kumar et al, 2010). This makes the case 
for the need to the understand all the complex interactions associated with molecular 
motors as it is crucial to the pathology of neurodegenerative disease. 
The heavy chain of cytoplasmic dynein, in particular, has been the protein of interest with 
over 20 mutations recorded to date and known to cause various neurological disorders in 
humans (Figure 2).  The dynein heavy chain is a 532 kDa protein encoded by a single 
gene, DYNC1H1 (Banks and Fisher, 2008). Interest in the heavy chain of dynein was 
further heightened with the generation of animal models by ENU mutagenesis named 
‘legs at odd angles’ or Loa , (Rogers et al, 2001 ) ‘cramping’ or Cra ( Hrabe de Angelis 
et al,2000) and the ‘sprawling’ mutation or Swl produced by irradiation (Duchen, 1975). 
There are some phenotypes that these early dynein mouse models have in common. The 
mice showed abnormal hind limb posture when suspended by the tail as well as abnormal 
gait and general muscle weakness. These mutations also disrupt dynein-driven retrograde 
transport involving various cargoes in one way or the other. As much as there are 
common features with the various mutations there are also unique the ways the function 
of the protein is altered based on where the mutation is in the heavy chain. (Hafezparast 
et al, 2003) reported the loss of motor neurons in both Loa and Cra heterozygote mice, 
(Dupuis et al, 2009) on the other hand reported sensory neuron degeneration in Cra 
heterozygous mice, (Chen et al, 2007) showed that Swl heterozygotes also lose 
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proprioceptive sensory neurons and muscle spindles. Experiments with homozygous mice 
from all 3 genotypes revealed severe defects in development, which explains why they 
are lethal at the embryonic stage.  Loa homozygotes showed delayed migration of 
neurons on the hippocampus and defects in the layers of the cortex (Ori-McKenney and 
Vallee, 2011). Homozygotes with the Cra mutation were found to have defects in 
morphology and arborization of dendrites culture from the striatum (Braunstein et al, 
2010). Embryos from Swl homozygotes were found to be abnormal and had 
developmental defects and died by E8.5. (Zhao et al, 2016).  
Actual human mutations in the dynein heavy chain documented over the years are 
characterized by developmental deficits and a dysfunction of parts of the neurological 
system (Schiavo et al, 2013). The incidence of malformations of cortical development 
(MCD) in 11 patients was traced to mutations in the dynein heavy chain (Poirier et 
al,2013). Some of the mutations possibly affect specifically the motor and sensory 
neurons and are characterized by weakness in the muscle and atrophy (Weedon et al, 
2011). In some cases, progressive muscle degeneration is observed classically referred to 
as spinal muscular atrophy with lower extremity predominance or SMA-LED (Harms et 
al, 2012, Tsurusaki et al, 2012). Some human mutations in the dynein heavy chain were 
found to cause severe intellectual disability (Willemsen et al, 2012). Another study 
employing exome sequencing of the dynein heavy chain uncovered 8 de novo mutations 
and 1 familial mutation from a screen of patients with various brain malformations such 
as microcephaly and abnormalities on the cortex (Poirier et al, 2013). 
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Figure 2 Schematic representation of mutations in the dynein heavy chain. 
The diagram shows the different mutations that have been reported to date in the dynein 
heavy chain (about 4644 amino acids). Human mutations are differentiated from the 
mouse mutations, P1-P5 represent the ATPase domains, and C represents the C-terminal 
end. 
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The wide phenotypic spectrum which has clearly become the hallmark of dynein –related 
disorders could be due to the multifarious roles of dynein inside the organism and in the 
case of neurological disorders, the transport of different cargos that impact different 
processes. These factors could determine the sensitivity of a group of neurons over the 
other and therefore predict which neurological function will be compromised. 
Different phenotypes are observed in human subjects with dynein heavy chain mutations, 
however the question of how and why still remains.  It is possible that it is a result of the 
myriad of roles that dynein performs in cells. While there is no simple straightforward 
answer, we can  learn a lot of useful information by relating the structure of dynein to its 
functions. It is important to investigate how mutations alter the dynein molecule and 
whether or not it’s functions are altered as a result. 
Evidence of the heterogeneity in phenotypes were initially observed in the animal 
models. For example, sensory deficits were seen in Swl  and Loa mice but not in mice 
with the Cramping mutation. There was a reduction in the number of alpha motor 
neurons in the spinal cord of Loa and Cra mice but no motor neuron loss was recorded in 
Swl mice (Banks and Fisher, 2008). Heterogeneity in the dynein heavy chain mutations 
was reiterated when 34 mutations were generated in Neurospora crassa (Sivagurunathan 
et al, 2012,) The length-dependent theory of dynein heavy chain mutations based on 
disrupted transport over long distances in axons would presume a bias towards the 
peripheral nerves instead of nerves in the brain or spinal cord. Yet, there are patients with 
deformities in the cerebral cortex and cognitive impairments all arising from mutations in 
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the dynein heavy chain. The effects of dynein heavy chain mutations on the CNS have 
previously been observed alongside peripheral neuropathies. For instance, in CMT2O, 
which predominantly manifests in muscle weakness and atrophy, at least 2 patients were 
reported with severe intellectual disability as a result of dynein heavy chain mutations 
(Weedon et al, 2011). 
1.3 Importance of Axonal Transport 
The distance that separates the soma from the synapse in neurons makes timely 
communication between these compartments very crucial. This issue of distance is 
accentuated by the fact that protein synthesis does not occur in some axons, hence the 
need to ferry the needed proteins from the soma. (Morfini et al,2009). The unique 
functions of dynein in neurons unlike the ‘so-called’ general housekeeping functions 
have been studied extensively as a result of phenotypes observed from many heavy chain 
mutations. 
Defects in axonal transport have been highlighted in relation to neurodegenerative 
diseases in amyotrophic lateral sclerosis (ALS) (LaMonte et al, 2002 & Strom et al, 
2008), spinal muscular atrophy (SMA), (Puls et al, 2008), Huntingtin disease (Trushina 
et al, 2004) and tauopahies (Ishihara et al, 1999, Ebneth et al, 1999). The cargos 
involved and the extent to which they facilitate disease progression varies. The transport 
of synucleins may play a role in the pathogenesis of Parkinson’s disease (Jenssen et al, 
1999), presenilin-1 and the amyloid precursor protein transport are important in 
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Alzheimer’s (Papp et al, 2002), and problems related to the transport of mitochondria 
accounts for some of the dynein associated mutations (Eschbach et al, 2013). 
Axonal transport is dependent not only on the motors but on other conditions, for 
instance the cytoskeleton. The neuronal cytoskeleton provides the structural integrity and 
due to its dynamic properties, the neuron is also able to change morphology and grow 
over time (Chevalier-Larsen and Holzbaur, 2006). The microtubules in the axon serve as 
the tracks for transport by molecular motors; dynein and kinesins transporting various 
cargo in the retrograde and anterograde direction respectively (Figure 3).   The rapid 
polymerization and depolymerization in microtubules is required for the axon and growth 
cone earlier in the developmental cycle. This however is significantly reduced in the 
mature neuron as the microtubules are stabilized more in part by microtubule associated 
proteins (MAPs). These features of MAPs are vital in regulating transport in the axon 
through the interaction of the molecular motors with the microtubules (Dixit et al, 2008). 
Although these motors have significant differences structurally as well as in their 
kinetics, experiments show that both kinesins and dynein’s are transported bidirectionally 
suggesting a mechanism for the regulation of their functions (Hendricks et al, 2010). 
Additionally, apart from cargo transported predominantly in one direction a number of 
organelles are transported by both dynein and kinesin in both directions.  Bidirectional 
transport of cargo may involve the attachment of  either dynein or kinesin molecules. 
This ensures that each motor is available for respective movement and prevents the 
situation where one motor will be stuck in one compartment of the cell and be unable to 
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move cargo when required. Kinesin–driven transport towards the synapse may 
translocate mitochondria, synaptic vesicles, axolemma precursors (Elluru et al, 1995, 
Leopold et al, 1992). Dynein is known to transport microtubules in neurons as 
experiments interrupting dynein transport revealed that the microtubules are stuck at the 
centrosome (Ahmad et al, 1998).  
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Figure 3 Microtubule based intracellular transport 
The molecular motors dynein and kinesin generate force within cells to transport various 
cargo such as vesicles, signaling molecules, RNA and mitochondria utilizing 
microtubules as tracks. The majority of kinesins move cargo away from the nucleus to 
the minus end, whereas cytoplasmic dynein is responsible for retrograde transport 
towards the nucleus. 
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Dynein and kinesin transport neurofilaments which provide structural support to the axon 
and dendrite and aids in the transmission of nerve impulses (Roy et al, 2000, Yuan et al, 
2015). It has also been suggested that some neurofilament proteins offer stability by 
interacting with synaptic proteins from the brain and peripheral synapses (Ralph and 
Nixon, 2016). The movement of cytoskeletal proteins ie. microtubules, actin, 
neurofilament is believed to be proceed at a much lower rate than organelle transport 
(Baas and Buster, 2004). This is probably needed to allow remodeling of the 
cytoskeleton at the growth cone, so that axons can be withdrawn if need be and 
reorganization of microtubule polarity in dendrites. 
In the developing neuron, dynein plays a role in neuronal migration via its interaction 
with other binding partners. (Sasaki et al, 2000) showed that the Lis1, which is the 
mutant protein in the neurological condition Lissencephaly or smooth brain, marked by 
abnormal cortical layering in the brain and large ventricles interacts with dynein and 
could possibly be a regulator of retrograde axonal transport. Neuronal migration defects 
were also confirmed in a dynein mutant mouse model by Ori-McKenney and Vallee, 
2011. Dynein was identified as part of the postsynaptic density (PSD) in the dendritic 
spines of rats (Cheng et al, 2006). This finding in addition to what is already known 
about the transport of synaptic components to the soma for recycling suggests a role for 
cytoplasmic dynein in the set up and maintenance of synaptic connections. Furthermore, 
synaptic plasticity is affected by the activity of dynein and kinesin motors via the 
transport of specific components (Yagensky et al, 2016). Cargoes transported by dynein 
aid in maintaining neuronal health and survival, for instance signaling molecules, 
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proteins to be recycled (Delcroix et al 2004, Susalka and Pfister, 2000). The clearing of 
misfolded proteins helps prevent their eventual accumulation and/ or aggregation which 
could have deleterious effects on the neuron. Signaling molecules could also be 
transported as receptor –ligand complexes and are vital in the signaling pathway that 
ensures survivals of neuronal cells (Harrington and Ginty, 2013).  
(Yano et al, 2001) reemphasized the important role of dynein in the neurotrophic 
signaling cascade when they reported the binding of dynein to the neurotrophic receptors 
TrkA, TrkB and TrkC. Brain –derived neurotrophic factor (BDNF) is one such 
neurotrophic factor known to control dendritic growth and morphology in cortical 
neurons (McAllister et al, 1997). When BDNF mediated transport is perturbed by 
dissociating dynein from the adaptor snapin, dendritic growth is reduced (Zhou et al, 
2012). Dynein is also instrumental in the lysosome degradation pathway. The transport of 
autophagosomes to the cell body by dynein allows them to mature as they acquire other 
components en route. (Maday et al, 2012). Jip-1 and huntingtin, which are major players 
in the transport of autophagosomes have been shown to associate with dynein and kinesin 
(Fu et al, 2014).  
There is growing evidence that supports the possibility of local protein synthesis in the 
axon, which largely stemmed from the identification of components of the protein 
synthesis apparatus (Steward and Levy, 1982, Giuditta et al,2002, Fumy et al, 2010). 
Axonal protein synthesis can be typically observed when there is an injury and there is 
the need to turn on biochemical and molecular switches to reprogram a growth cone for 
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axonal regeneration (Yoo et al,2010). All of this means that mRNA and indeed 
components of the translation machinery must be transported to the site of translation, 
this is accomplished by dynein and kinesin activity (Zhang et al, 2001). Further 
involvement of dynein in mRNA transport is seen with RNA granules, which are 
complexes of mRNA plus other proteins that help target it to a specific location (Bassell 
and Kelic, 2004). Stress granules contain ribonucleoproteins and enable the cell mount up 
the appropriate response under harsh conditions like toxin exposure, elevated 
temperature, and factor generally repress translation in one way or the other (Kedersha 
and Andersen,2002). In spinal cord neurons subjected to arsenite stress, dynein was 
discovered to be key not only in the composition of stress granules but equally in the 
disintegration of the complexes as well. (Tsai et al, 2009. Loschi et al, 2009). Axonal 
transport is central to a lot of the processes in the neuron that promotes its survival, and it 
is also important in the pathology of neurodegenerative diseases as a whole; during both 
the subtle and overt stages. Exploring how these diseases influence the intricate 
interactions of motor proteins like dynein with different cargoes and accessory proteins 
will be key to the development of effective treatment and management solutions.  
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1.4 Charcot Marie Tooth Disease 
Charcot-Marie-Tooth disease (CMT) is named after 3 neurologists, Jean-Martin Charcot, 
Pierre Marie and Howard Tooth, who discovered it in 1886 (Daroff et al, 2012). The 
disease also referred to as hereditary motor and sensory neuropathy (HMSN) describes 
multiple inheritable motor and sensory neuropathies affecting various proteins (Figure 4. 
Pareyson and Piscosquito, 2014). 1 in 2500 individuals are believed to be affected by 
CMT disease (Nelis et al,1996), making it the most common inheritable peripheral nerve 
disorder worldwide (Magy and Vallat, 2015). To date over seventy genes have been 
implicated in the different types of CMT disease. Electrophysiological readings led to the 
broad classification of the forms of the disease as either demyelinating (CMT1) and non-
demyelinating (CMT2) or Axonal (El-Abassi and Carter, 2013). CMT1 involves 
mutations in genes encoding myelin proteins or transcription factors for example 
PMP222, MPZ, and CX32. When proteins that function in the maintenance of the axon 
are affected, it is classified as CMT2. Some examples are CMT2B (mutation in the 
KIF1B kinesin gene), CMT2B (mutation in RAB7) and CMT2E (mutation in 
neurofilament gene NEFL) (Zhao et al, 2001, Meggouh et al, 2007, Mersiyanova et al, 
2000). CMT disease reduces the quality of life of its sufferers since they have to deal 
with limited mobility arising from distal limb weakness, deformity and pain. Some of the 
common deformities include pes cavus, pes planus and hammer toes (Figure 5, Pareyson 
and Marchesi, 2009, Tazir et al, 2014). Less common features like gait problems and loss 
of sensation in the hands and feet can also impose further difficulty on patients. CMT 
disease has a variable onset based on patient data and usually begins with muscle 
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weakness and atrophy of the feet and then slowly advances to the upper limbs 
(McCorquodale et al, 2016).  
1.4.1 Diagnosis 
Due to the heterogeneity of the phenotypes and variable onset in some cases, physicians 
cannot rely heavily on family history. As a result, genetic testing has proved invaluable in 
the diagnosis of CMT disease. Clinical evaluation may also involve investigating sensory 
and motor symptoms, muscle strength in the arm and leg and nerve conduction velocities. 
Advances in sequencing have proved useful with the use of DNA arrays, exome 
sequencing and next generation sequencing in genetic tests. 
Nerve conduction velocities (NCVs) above 38 m/s are classified as CMT2 whereas 
demyelinating CMT1 NCVs are usually less than 38m/s. Mid-point values from 36-45 
m/s are categorized as Intermediate CMT or X-linked CMT (Hoyle et al, 2015). Thus, the 
electrophysiological test is needed to distinguish the demyelinating form from the non-
demyelinating form to help inform the most appropriate treatment regimen. Research into 
therapeutic options for the various forms of CMT diseases to a very large extent depends 
on the genes or proteins involved and the cellular processes that are altered (Figure 4). 
For instance, in animal models of CMT1A, vitamin C and progesterone antagonists have 
been found to limit the expression of PMP22. These results however were not replicated 
in human subjects (Sereda et al, 2003, Gess et al, 2015). Other strategies involve 
targeting ligands, inhibitors or receptors involved in transducing signals downstream of 
the affected genes. Targeting the genes of interest poses a challenge in subtypes of the 
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disease with multiple mutations, like CMTD, where there are about 15 reported mutations 
in the enzyme glycyltRNA synthetase (GlyRS) (He et al, 2011).  Gene therapies 
comprising the use of induced pluripotent stem cells (IPSCs), RNA antisense 
technologies aimed at modifying gene expression could provide more promising 
outcomes. More extensive research is required regardless of the strategy, to move these 
remedies successfully from the pre-clinical to the clinical phase. 
1.4.2 Management 
Clinically, physical therapy and exercise are commonly employed in managing the 
associated symptoms of CMT disease. Gait, balance and posture can be corrected after 
consistent application so that the risk of injury or fall is greatly reduced. These exercises 
are helpful in reducing the stiffness in affected muscles and can be important in 
preventing deformities in the limbs later on in life. (Mathis et al, 2015). Some ankle and 
foot deformities such as pes cavus and hammertoes require surgical interventions due to 
their severity. Physical and occupational therapists offer assistive or orthotic devices such 
as special shoes, braces, crutches and canes to ease mobility in patients (Bird, 2016). 
Orthoses can help provide extra support to the local site affected and compared to 
surgical procedures, serve as simpler, non-invasive procedures to manage the cognate 
symptoms of CMT disease. In designing physical activities for neuromuscular disease 
patients, it is highly recommended to start with low-intensity exercises rather than high 
intensity regimens (Abresch et al, 2012). This allows relief and/or recovery to occur at a 
steady pace over a period of time without compounding the symptoms. 
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Figure 4 CMT target genes affected and cellular processes involved 
Many genes account for CMT disease phenotype. Mutations affecting proteins in the 
Schwann cell are classified as the demyelinating form of CMT, while those affecting 
axon and cell body proteins fall under the non-demyelinating category of CMT disease 
(Jerath and Shy, 2015). 
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Figure 5 Classical features of Charcot Marie Tooth Disease 
CMT disease impairs ion of motor and sensory nerves resulting in a range of phenotypes 
that mainly affect the lower limbs and the hands in some cases. (a,b)Atrophy of the 
muscle in the lower limbs, (c) pes cavus (d) hammertoes, (e) callosities of the foot and (f) 
claw hands (Pareyson et al, 2009)
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Efforts directed towards pharmacological interventions have not been so successful, for 
example initial findings about ascorbic acid for the treatment of CMT1A looked 
promising but actual data from patients did not show much improvement in their health 
(Visioli et al, 2013).   The plant –derived curcumin compound that is known to have 
multiple therapeutic effects was found to boost the production of Schwann cells by 
reducing myelin protein zero protein misfolding (Patzko et al, 2012). Mice bearing 
mutations in the heat shock protein HSPB1 recorded modest improvements in some 
symptoms when histone deacetylase 6 (HDAC6) inhibitors were administered. HDAC 
inhibitors alter the transport defects through tubulin deacetylation (d'Ydewalle et al, 
2011). In CMT1A rats, there was an observed amelioration of the disease phenotype 
when a progesterone antagonist, onapristone was administered. Onapristone reduces the 
levels of the Pmp22 gene which is normally overexpressed in CMT1A disease (Sereda et 
al, 2003). However, onapristone could not be used in humans due to its toxicity, 
prompting the need for further studies into alternative progesterone antagonists 
(Shy,2006). Going beyond just CMT1A, scientists are looking into different strategies 
and approaches to find remedies that can work in humans. One example of such is a 
massive drug screen involving 3,000 drugs in a high throughput screen that led to a 
shortlist of 9 with significant activity against different targets. More toxicity studies 
excluded 5 of them, leaving just 4 suitable compounds (Jang et al, 2012). Although this 
screen was specifically targeting modulators of myelin genes it is worth looking into for 
other forms of CMT disease. 
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Dietary supplements like some essential fatty acids, vitamin E as well as the drug 3, 4-
diaminopyridine have been experimented as treatment options, but once again they are 
not backed by convincing data in patients (Williams et al, 1986 & Russell et al, 1955). 
One major challenge that has hampered the search for remedies in the past has been the 
absence of adequate historical records on the disease. This is because sometimes 
symptoms are observed late, as the disease progresses slowly. Also,it is possible patients 
were previously misdiagnosed when parameters were not clearly defined. This has been 
addressed to some extent with the emergence of focused groups like the INC 
(International Neuropathies Consortium) which are working hard to collate data on 
patients (Gutman and Shy, 2015). Another initiative to ensure success in dealing with 
CMT disease is to encourage collaboration among health experts; neurologists, 
geneticists, physiatrists and orthopedic surgeons to provide more holistic care and to 
possibly give patients a better quality of life. (McCorquodale et al, 2016). Such 
collaborative efforts facilitate data sharing and enables providers monitor disease 
progression and patient recovery more closely.  
1.5 Skeletal Muscle Function 
Voluntary movement in the body is achieved through striated cardiac and skeletal 
muscles (Kho et al, 2012). Skeletal muscles attach to the bone via connective tissues and 
are responsible for the movements of bones at a joint. Skeletal muscles therefore possess 
tensile and contractile properties that enable them to support movement. These are made 
possible by a myriad of cytoskeletal and structural proteins that are well regulated with 
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coordinated functions to obtain the proper assembly. Sheets of connective tissue known 
as fascicles, cover multiple muscle fibers organizing them into bundles. Skeletal muscles 
have numerous nuclei, distinguishing them from other cell types. However, they possess 
organelles such as mitochondria, endoplasmic reticulum, and glycogen granules just like 
other cells in the body (Fox, 2011). 
1.5.1 Muscle Sarcomeres 
Sarcomeres are the units of contraction in skeletal and cardiac muscle (Goulding et al, 
1997). The highly ordered patterns account for the striations in these muscle types. The 
proper assembly of various proteins into the final ordered structure is indispensable in the 
maintenance of proper muscle structure and function. The components of the sarcomere 
appear as bands or lines under the microscope. There are 4 main components of the 
sarcomere; Z-line, I-band, A-band and M-line (Figure 6). The Z-line delineates the 
sarcomere and consists of proteins such as alpha-actinin, capZ, desmin and myotilin that 
serve as attachments of the thin filaments. The I-band is made up of mainly actin and 
other associated proteins including troponin, tropomodulin and nebulin. The region 
consisting of mainly thick myosin filaments and thin filaments is referred to as the A-
band. Contraction of the muscle occurs when the sarcomeres shorten due to the sliding of 
the myosin filaments over actin. (Cadot and Gomes, 2016). At the center of the A-band, 
are a group of specialized proteins belonging to the myomesin family that make up the 
M-line or M-bridge (Henderson et al, 2017). These function to provide stability to the 
myosin heavy chain and in sensing and transducing intracellular signals. 
 The highly ordered sarcomere lattice would suggest a fixed, rigid structure, however, it 
can undergo reorganizations in response to different cues like stress or injury.  
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1.5.2 Myonuclei and Muscle Development 
Skeletal muscle fibers are characterized by numerous nuclei and units of contraction 
known as sarcomeres in tandem which account for the striations. The muscle nuclei are 
maintained over a range of specific internuclear distances possibly to mark out domains 
for more efficient transcriptional control (Bruusgard et al, 2003, Pavlath et al,1989).The 
debate as to whether nuclei number is related to the size of the muscle fiber is still pretty 
much unresolved, especially when it has been observed that increase in muscle size is not 
always accompanied by a large presence of myonuclei (Verheul et al,2004; Aravamudan 
et al, 2006). Progenitor cells in the muscle known as satellite cells are positioned between 
within the basement membrane and sarcolemma. Their location within the vicinity of 
myonuclei at the periphery, likely enhances the replacement of damaged nuclei in the 
event of an injury (White et al, 2010). The maintenance of a maximum number of nuclei 
marks the attainment of maturity in the muscle and is necessary for muscle functioning 
(Davis and Fiorotto, 2009). This makes satellite cells therapeutic targets for the treatment 
various neuromuscular disorders if their regenerative capacity can be harnessed. There 
are several factors that influence proliferation in satellite cells; muscle type, age and 
chemical modulators (Manzano et al, 2011). Testosterone for instance, enhances the 
proliferation of satellite cells and increases muscle nuclei abundance in rats (Joubert 
&Tobin, 1989). The satellite cells maintain an actively dividing population during 
development, and a smaller population that stays in a quiescent mode. The larger 
proliferating group is high in numerosity and most active during early postnatal days 
accounting for the high cell number, after which both number and activity decline in 
adulthood (Neal et al, 2012). 
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Nuclei positioning is very important for the normal functions of the muscle fiber, 
conversely, the misalignment of the nucleus is linked to disorders of the muscle 
(Gueneau et al, 2009, Romero,2010). Molecular motors, microtubules and a host of 
adaptors and regulators are responsible for the placement of nuclei in different cell 
systems. Work done in the muscles of Drosophila points to joint roles by both dynein and 
kinesin in positioning nuclei (Folker et al, 2014). This study proposed a mechanism with 
segregated roles for the motors where their ability to generate force is harnessed at 
leading and trailing ends of the migrating nuclei. In mutant Drosophila embryos with 
impaired dynein and kinesin function, changes occurred in the shape of the nuclei and the 
pace of myonuclei transport was much slower. 
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Figure 6 Illustration of the contractile unit of the muscle  
Long tubular structures called myofibrils make up each muscle fiber, and these 
myofibrils possess repeating sarcomeres. The distance from one Z-line to the other 
represents the length of one sarcomere. Thick and thin filaments overlap on the A-band. 
The I-band has only thin filaments and the H-zone only has thick filaments whose center 
is marked by a group of proteins constituting the M-line. 
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Figure 7 Nuclei placement in muscle fibers 
Muscle fibers stained in red and DAPI-stained nuclei (blue) from a wild-type mouse 
muscle tissue. Nuclei are normally positioned at the periphery of the muscle nuclei based 
on the need to maintain transcriptionally controlled sections within the fiber. When there 
is some muscle pathology, the arrangement could be disrupted leading to the presence of 
more centrally-positioned nuclei within the muscle fiber. 
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1.5.3 The Neuromuscular Junction 
The neuromuscular junction (NMJ) is a peripheral synapse that maintains the connection 
between the motor neurons and muscle fibers. This connection ensures that action 
potential initiated by the nerves are carried across to ensure contraction of the muscle 
(Tintignac et al, 2015). The formation and maturation of the NMJ consists of a myriad of 
molecular events that are well regulated and coordinated by key players. This multitiered 
set up also makes it vulnerable to disease at diverse levels when the normal functions are 
disrupted. Disorders of the peripheral nerves such as Charcot Marie Tooth Disease, 
SMAs, myasthenias and muscular dystrophies usually affect the neuromuscular junction, 
making it important in understanding the pathology and progression of disease. Mutations 
that affect signaling pathways that control the maturation and stability of the synapse or 
the withdrawal of nerve inputs can all interfere with the normal functioning of NMJs and 
lead to muscle weakness, fatigue, atrophy and paralysis in very severe cases (Ferrraro et 
al, 2012). The setup of the peripheral synapse begins with motor axons making contact 
with their muscular target once the myotubes fuse to form the myoblasts. (Lin et al, 2001) 
observed that majority of the AChRs are innervated by E13.5, with complete innervation 
of all AChRs achieved by E16.5. Transmission at the synapse occurs once the growth 
cones of the motor axons reach the myotubes. The NMJ at this point is functional and is 
characterized by having multiple inputs from a number of axons at the time of birth.  
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Figure 8 The developmental timeline of neuromuscular junctions in mice 
Motor neurons contact muscles by E12.5 after the myoblasts fuse to form myotubes. 
Terminal Schwan cells start move towards the end-plate some time before E15. Acetyl 
choline receptors also cluster as the axons approach the myotubes. One of the most 
significant changes that occurs afterwards is the shift from poly-innervated muscle fibers 
to single innervated fibers beginning from birth to P14. (Bloch-Gallego, 2015) 
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1.5.3.1 Synapse Maturation 
The most noticeable feature is the change in shape or morphology of the post-synaptic 
apparatus, from a solid plaque to a highly-branched structure commonly referred to as the 
‘cookie to pretzel transformation’. The end plate, which was previously flat is elevated to 
form gutters or troughs. There is also an increase in other cellular components at the end 
plate which help make it more stable, some of these include the basal lamina and various 
cytoskeletal proteins. The AChRs undergo a change in Ca permeability that favors the 
initiation and generation of action potential. Similarly, the ion and ligand gated channels 
are also reorganized to achieve the same purpose. Structural changes occur as the AChRs 
mature; the most significant is the replacement of the γ – subunit to an ε- subunit. The 
morphology of AChR clusters at the endplate also changes during maturation. Nerve 
inputs are withdrawn till the end plate has just one input. The transition from an immature 
polyinnervated apparatus into the fully-developed form in the adult is responsible for the 
rearrangement of AChR structure (Figure 8. Sanes and Lichtman, 1999). Further changes 
occur as the muscle fiber increases in surface area due to growth. The invaginations that 
develop are typically about 1um deep and are spaced at 3um from one another. The 
AChRs located on the crests of the folds are as a result easily accessible to the nerves. 
Another major change in the mature post-synaptic apparatus is the subunit change that 
occurs in the AChR. One subunit out of the pentamer (α2βδγ), specifically the γ-subunit is 
traded for an ε-subunit (α2βδε) to make the receptor more stable (Missias et al, 1996, 
Sanes and Lichtman, 2001). 
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1.5.3.2 Transmission of Nerve Impulses 
Innervation of the muscle by motor neurons is critical for normal functioning and 
structural development of the peripheral synapse. The innervation precedes the cascade of 
molecular events that occur to ensure the proper development and maturation of the NMJ. 
In a functional neuromuscular synapse, the transmission of signals in the post-synaptic 
compartment is facilitated by a surge in the number and density of acetyl choline 
receptors at the end plate. The acetylcholine receptors (AChR) can accumulate up to over 
10,000µm2 in density in the synaptic zones. This number is vastly different from regions 
farther away where the density is approximately 10µm2 (Sanes and Lichtman, 1999). 
Subsynaptic nuclei located beneath the receptors are partly responsible for this 
phenomenon. These nuclei positioned at the NMJ in clusters of between 3- 8 nuclei 
maintain a transcriptional profile distinct from nuclei outside the synaptic region and 
transcribe genes needed for the developing NMJ (Simon et al,1992, Briguet and 
Ruegg,2000). The reorganization and specification that occurs in and around the synaptic 
region is achieved via three pathways. Agrin is released by the nerves and it binds to the 
muscle specific receptor tyrosine kinase (MuSK) present in the muscle. This leads to 
other downstream events that result in the clustering of acetyl choline receptors. 
Preferential expression of AChR genes in the synaptic nuclei also occurs and this is 
mediated by neuregulin and erbB kinases. The upregulation in transcription of AChR 
genes requires the suppression of gene expression in regions outside of the synaptic 
region. Acetyl choline binds to AChRs to trigger the influx of calcium and the generation 
of a voltage –dependent signal to down regulate the expression of genes. The nerves were 
initially thought to be required for clustering of the acetyl choline receptors in the initial 
stages of development. (Lin et al, 2001) examined neuromuscular junction development 
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early at E14.5 and identified a concentration of AChRs, suggesting that neural cues may 
not be needed to initiate NMJ development. This observation confirmed what was 
previously reported by other researchers (Lupa and Hall, 1989 & Dahm and Landmesser, 
1991). Experiments with mutations in the MuSk show it is a major player in the neural-
independent post synaptic organization seen early in development. That notwithstanding, 
the nerve input is required for further development and maintenance of the 
neuromuscular junction.  The involvement of the MuSK pathway in initiating synaptic 
differentiation help explains why mice lacking the receptor die at birth, and why 
mutations lead to congenital myasthenic syndrome in humans (Dechiara et al, 1996 and 
Chevessier et al, 2004). MuSK depends on agrin binding to dimerize and activate its 
kinase activity. Further downstream, other kinases responsible for the phosphorylation of 
the AChR subunits are also activated. A membrane protein which associates with the 
AChRs known as Rapsyn or Receptor-associated protein at the synapse is vital in AChR 
clustering. Studies into the precise function of Rapsyn indicate that it is required for 
phosphorylation of AChRs. The cytoskeleton is another crucial factor in triggering AChR 
clustering. The MuSK-agrin path way mediates the positioning of the receptors on actin 
filaments after they have undergone some rearrangements. This process may be important 
to provide additional stability to entire post-synaptic apparatus (Strochlic et al, 2005). 
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1.5.4 The Role of Glial Cells at the Neuromuscular Junction 
The peripheral synapse is a tripartite system consisting of the motor neuron, acetylcholine 
receptor and perisynaptic Schwann cells (PSCs) also known as terminal Schwann cells. 
Details about the exact functions and mechanisms of these specialized Schwann cells 
located at the synapse are still being uncovered. The glial cells associated with the 
peripheral synapse differ from myelinating Schwann cells in many ways: the most 
obvious being location with the PSCs covering the nerve terminal and the myelinating 
Schwan cells wrapping around the axon further upstream, accounting for saltatory 
transmission of nerve impulses. Both myelinating and non-myelinating Schwann cells 
share similar proteins or markers such as myelin-associated glycoprotein, myelin protein 
zero (MPZ), galactocerebroside and 2′,3′-cyclic nucleotide-3′-phosphodiesterase 
(CNPase) (Feng & Ko, 2008). Mature PSCs however uniquely express genes not found in 
myelinating glia such as LNX1, an E3 ubiquitin ligase (Young et al, 2005) and Nav 1.6 
(Musarella et al, 2006). These biomarkers have proved very useful in the investigation of 
PSCs and their effects on NMJ development. PSCs possess more neurotransmitter 
receptors and ion channels in addition to receptors for ATP and acetylcholine. They also 
produce chemicals like nitric oxide, prostaglandins and glutamate, which regulate 
synaptic communication (Auld et al, 2003). The density of PSCs at the NMJ significantly 
increases as the animal progresses to adulthood, possibly in response to roles in the 
maintenance and proper functioning of the synapse (Love and Thompson, 1998).  
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Figure 9 Glial cells at the neuromuscular synapse 
Non-myelinating glial cells, also known as terminal Schwann cells (stained in red) are a 
part of the tripartite apparatus of the peripheral synapse. Terminal Schwann cells play a 
role in the maintenance of NMJs and guide resprouting axons to their target.  
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1.5.4.1.1 Roles of PSCs in the developing NMJ 
PSCs and axons make their way early to the muscles at about the same time in the 
developmental timeline. There is evidence to show that although the nerves still 
successfully associate with muscles, they are significantly defasciculated when PSCs are 
ablated (Suguira and Lin, 2011). Whilst the axons may not need the PSCs to locate their 
targets, they start to retract when the PSCs are depleted from the NMJ. Thus, PSCs may 
rather be important in maintaining the neuromuscular synapses through various means. 
PSCs were found tightly associated with the AChR dense areas in developing NMJs up to 
14 days after birth. More probing revealed how they assist in input removal through the 
phagocytosis of nerve terminals (Smith et al, 2013). This is explained by the ability of the 
PSCs to sense the strength of synaptic inputs from incoming nerves at polyinnervated 
NMJs (Jahromi et al, 1992; Darabid et al, 2013). Researchers have been interested in the 
molecular switches that regulate the PSCs in the course of development and how that 
affects neuromuscular function as a whole. ErbB2 is a tyrosine kinase receptor which acts 
downstream of neuregulin and is normally found in Schwann cells and muscles during 
NMJ development. Studies with erbB2 deficient mice revealed not only aberrations in 
NMJ development but the loss of Schwann cells at nerve terminals of developing 
embryos. The mice also die at birth most likely because of breathing difficulties caused 
by neuromuscular anomalies in the diaphragm (Lin et al, 2000). The removal of PSCs 
adversely affects neuromuscular junction development as the nerves of the muscle retract 
and the motor neurons degenerate (Wolpowitz et al,2000).  
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1.5.4.1.2 Roles of PSCs in the mature NMJ 
A lot of what is now known about PSCs came from studies with frogs (Rana pipiens), 
although they differ from rodents in many ways. In frogs, the PSCs extend long 
projections into the synaptic area and the amphibians PSC is maintained in a dynamic 
state and are actively involved in transforming the entire NMJ structure, this contrasts 
with the relatively more stable set up in mammals (Ko and Robitaille, 2015). Injury or 
damage to the nerve also triggers the phagocytic activity of the PSCs. This process clears 
debris and guides axons to reinnervate the muscles. Through a similar mechanism, PSCs 
isolates surrounding connective tissue and basal lamina when there is an injury, or even 
when the axon is severed. The axon is unable to initiate its own regeneration and depends 
on the PSCs and other key players to make contact again with target cells. In the 
Schwann cells of both adult frogs and rodents, there are receptors for the binding of Ca2+ 
and ATP (Parinello et al, 2010). The presence of muscarinic and purinergic receptors in 
PSCs makes it possible to modify Ca levels and ultimately the expression of specific 
genes. PSCs generally influence NMJ structure and function often with the input of 
upstream signals. Neuregulins, for instance via the erbB kinases trigger changes in the 
Schwann cells that maintain efficient synaptic transmission and stabilize motor terminals 
(Trachtenberg and Thompson, 1997). PSCs produce neuronal factors that stimulate a 
cascade of downstream events. Neuregulin-2, required for transcription by acetyl choline 
receptors and agrin, an inducer of receptor aggregation, are expressed by PSCs (Yang et 
al, 2001, Rimer et al, 2004). It is safe to speculate that expression of these factors allows 
the maintenance of the NMJ to continue even after maturity, or it may be a backup 
mechanism during denervation or neuronal injury. 
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1.6 Animal Behavioral Assays 
The use of standardized protocols to examine the phenotype of animals with mutations 
has become valuable in establishing disease model systems and in translational research. 
These protocols allow the mutant animal to be pathologically characterized to either 
confirm or rule out the existence of disease. The benefits of standardized phenotypic 
assessment of animals include the possibility of differentiating spontaneous and induced 
mutations, strains of animals and analyzing the impact of transgenic or genetically 
manipulated models of disease (Rogers et al, 1997). There are certain conditions that 
must be generally satisfied regardless of the specific application of behavioral 
assessment. It is vital to avoid partiality by keeping benchmarks for all groups, and these 
include but are not limited to, initial time point and endpoint, features or characteristics to 
be examined, a scoring system if needed and an accurate record keeping system 
maintained for all tests carried out. Behavioral assays also cover observations on the 
morphological characteristics of the cohort; body mass, body length and notes on the 
functional activities as well. An often-used well-designed system for behavioral testing is 
the SHIRPA analysis (Rogers et al,2001). This comprises a protocol involving three 
stages of screening to assess neurological impairments in an animal. This can be very 
useful in cases where it is not possible to predict exactly which system will be affected 
for instance, whether there is more of a sensory deficit or a cognitive deficit in the case of 
neurological disease models. The initial screen of SHIRPA is based on observation of the 
general health of animals for features like hair color, gait, posture, excitability, 
aggression, defecation, salivation etc. It is a general analysis that also requires a scoring 
system to properly document findings. The next level of screening is more detailed and 
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targets an underlying pathological condition. Motor performance, balance and 
coordination and nociception are some of the measurements that can be taken and these 
can be done with the appropriate measuring device or equipment. Histopathological 
procedures, biochemical analysis of plasma or serum for metabolic investigations are 
done at this level of analysis. The third of level of screening is custom-made for a known 
condition that does not necessarily require a battery of assays to establish the presence of 
a phenotype.  At this stage investigators will be interested in defects of a cognitive or 
psychiatric nature. The assays are usually for more specific conditions, anxiety for 
instance can be measured with the open-field activity test, elevated maze or light-dark 
box; learning and memory defects can be examined with the Morris water maze. At this 
final stage of screening some other techniques like nerve conduction, electromyography, 
electroencephalography and magnetic resonance imaging could be utilized. 
The reproducibility of behavioral data is important like in any other assay for that matter, 
for that reason it is important that the environment in which these tests are carried out are 
carefully controlled to limit sources of variation. Concerns about a valid environment are 
validated by data suggesting interactions between genes and external factors in the 
environment (Gottlieb, 1998).  The environmental conditions are within the power of the 
investigator as well as associated parameters as standard equipment, protocol, husbandry 
conditions etc. These as potential sources of variability can be eliminated by 
standardizing experimental parameters for all test groups. The situation is quite different 
from more intrinsic factors that have to do with the neighboring genes where the mutation 
is found and the effects that could arise from using a strain of the organism or animal 
from a particular genetic background (Wahlsten, 2001). 
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Figure 10 Examples of behavioral assays used in assessing motor phenotype in mice 
A) The rotarod is useful for determining motor coordination B) The grip strength meter 
records the muscle strength C) The tail suspension assesses hind limb posture as a reflex 
response when mice are suspended by the tail D) The suspended pole tests balance and 
muscle strength E) foot print assay is for gait analysis F) the wire mesh tests balance and 
muscle strength in the limbs of mice 
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 Records of past experimental procedures from literature are a good starting point in other 
to pick a particular background for genetic manipulation. It might be just easier to 
maintain the same genetic background for a related mutation. A lot of pointers can be 
obtained from research geared at ascertaining the effects of multiple factors on the 
accuracy of behavior data. They can help inform an investigator on the experimental 
design or choice of assays. (McIlwain et al, 2001) in one such study, looked at the effects 
of serial testing (using different assays) on mice and whether or not the sequence of the 
assay also had any effects on the output. There were both similarities and differences in 
mice that performed single assays versus those that did multiple assays. There were 
however fewer differences resulting from the order of assays when two groups of mice 
were compared. Deductions from studies of this nature always require caution, after the 
factors are meticulously examined. In making decision regarding an experiment, every 
investigator must pay attention to the results obtained making use of relevant statistical 
tools and analysis to scrutinize the data obtained in several ways to erase doubt. 
The choice of a behavioral test is obviously made based on the expected phenotype of the 
animal, and as such the right tool or equipment for the assay has to be picked as well. 
Regarding the equipment, it is possible to design an apparatus that achieves the same goal 
with certain tests thereby save cost from not purchasing an automated device (Figure 10). 
There are number of advantages with an automated system compared to non-automated 
ones. Scores can be done more accurately, and this enhances the chances of data 
reproducibility, the investigator or tester interferes very little on the process, it can be 
more efficient and drastically reduces the expense of energy (Hanell and Marklund, 
2014). The caveat however with an automated procedure is to find ways of verifying the 
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data, making sure it makes sense and satisfies metrics like trends and normal distribution. 
It may be therefore helpful to consider the level of automation, in such circumstances a 
process that is almost completely automated would necessarily analysis of the output data 
to ensure that it makes scientific sense. 
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CHAPTER 2:MATERIALS AND METHODS 
2.1 Generation of DYNC1H1 H304R Knock-in Mouse Model  
An 8.04 kb region used to construct the targeting vector was subcloned from a positively 
identified C57BL/6 BAC clone (RP23:60K23). The BAC was subcloned into a 2.45 kb 
backbone vector (pSP72; Promega) containing an ampicillin selection cassette for 
retransformation of the construct prior to electroporation. The region was designed such 
that the long homology arm extended 5.3 kb 5′ to the point mutation (A to G) in exon 5 A 
pGK-gb2 FRT NeoR cassette was inserted into the gene in intron 5–6. The short 
homology arm extended 2.05 kb 3′ of the FRT-flanked Neo cassette.  
The CMT2O mutation CAC to CGC (mouse aa304: His to Arg) within exon 5 was 
generated by 3-step PCR mutagenesis. Four primers, PT1 – 3 and LUNI, were designed 
and used to amplify a ∼2.5 kb fragment that incorporated the mutation at the desired 
position. The point mutation was engineered into primers PT2 and PT3. The final PCR 
fragment carrying the point mutation (middle arm) was then used to replace the wild-type 
sequence using conventional sub cloning methods at an endogenous enzyme site, MfeI, 
and at a MluI site in the Neo cassette. The targeting vector was confirmed by restriction 
analysis after each modification step, and by sequencing using primers designed to read 
from the selection cassette into the 3′ end of the middle arm and the 5′ end of the SA. 
Sequencing showed the presence of the mutation and that no errors were introduced in 
the PCR amplified region (Sabblah et al, 2018). 
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The targeting vector was linearized and electroporated into C57BL/6 × 129/SvEv hybrid 
embryonic stem cells. After selection by G418 resistance, surviving colonies were 
expanded and screened for recombinant clones by PCR using primers LAN1 and A1. 
Positive clones had the presence of the point mutation confirmed by a second round of 
PCR screening using primers SQ1 and LUNI followed by sequencing of that PCR 
product. Integration into the correct genomic location was confirmed by southern blot 
analysis. Three clones were confirmed as integrated into a parental chromosome at the 
targeted site and were then used for implantation (Sabblah et al, 2018). 
Positive stem cells were microinjected into C57BL/6 blastocysts. The blastocysts were 
transferred to pseudopregnant foster mothers and chimeras were obtained. Those 
chimeric mice were crossed to mice constitutively expressing Flp recombinase to produce 
F1 heterozygous knock-in targeted, NeoR cassette deleted mice. PCR was used to 
confirm the deletion of the Neo cassette and sequencing of the four founder mice 
confirmed the presence of the point mutation (Sabblah et al, 2018). 
2.2 Mouse Breeding and Colony Management  
Four founder animals (F1) with the confirmed H304R/+ mutation from InGenious 
Technologies were crossed to Jackson Laboratory mouse hybrid strain, C57Bl6/129 
(Stock # 101045) generating wildtype and H304R+/R mice. The animals were out 
crossed to the C57Bl6/129 strain up to the F7 generation. The progeny of these mice were 
used to breed the behavioral group for this study. Animals were bred in pairs and/or trios 
for behavior and tissue harvest. Founder females were bred with one male whereas 
founder male was bred with either one or two Jackson wildtype females. Females were 
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checked for pregnancy twice/ week. Males were housed singly for one week prior to 
breeding. Females were housed in pairs or groups until paired with a male. Females that 
did not produce a litter after three matings were removed from the breeding pool. Both 
males and females were bred from 6-8 weeks old. Males were retired from breeding after 
1 year and females were retired from breeding after 6 litters or 5 months whichever came 
first. The animals were housed in microisolation cages with ad libitum access to food and 
water under controlled temperature (22±2 °C) and humidity (50±10%) and maintained on 
a 12-hour light/dark cycle. All mice were given red housing for environmental 
enrichment (Sabblah et al, 2018).  
All females were examined for plug positivity and the males were removed. The pups 
were weaned on post-natal day 21. The animals were uniquely identified by tail tattoo 
using SoMark Tail Tattoo system (SoMark Innovations, San Diego, CA). Tail snips were 
taken at the time of tattoo. The tail snips were genotyped using PCR to determine the 
genotype of the animals.  
Western blot analyses were performed to determine if the H304R mutation altered the 
amount or stability of dynein molecules in brain tissue. Brain tissue from wild-type and 
H304R/+ male mice was homogenized in 35 mM PIPES pH 6.96, 5 mM MgSO4, 1 mM 
EGTA, 0.5 mM EDTA supplemented with 1 mM dithiothreitol, 0.2 mM ATP, and a 
protease cocktail. A high-speed supernatant of each sample was generated by spinning 
the samples in an SW50.1 rotor for 30 minutes at 40,000 rpm. The samples were run on 
SDS-PAGE gels, blotted and probed using standard techniques, utilizing antibodies 
against dynein intermediate chain (clone 74.1, BioLegend) and glyceraldehyde-3-
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phosphate dehydrogenase (clone O411, Santa Cruz Biotechnology) as a loading control 
(Sabblah et al, 2018). Signal was detected using goat anti-mouse secondary antibody 
conjugated to horseradish peroxidase (Invitrogen) and the ECL Prime Western Blot 
Detection Reagent (Amersham). Signal was captured on X-ray film and quantified using 
NIH ImageJ software (Sabblah et al, 2018). 
 
2.3 Motor behavioral assays  
Mice were given motor skills behavior tests every two weeks beginning at 1 month of 
age. The researchers performing the behavioral tests were blinded to the genotype of the 
mice they were examining, and the mice were only identifiable by tail tattoo codes.  The 
tail suspension test was performed by gently lifting a mouse by its tail for 15 seconds. 
The test mouse was recorded from both ventral and lateral angles to fully capture the tail 
suspension reflex. The recorded tail suspension videos were then analyzed, and each test 
was scored into one of two categories: typical or atypical response.  Mice exhibiting a 
typical response had their hind limbs splayed apart from each other and held away from 
the body (Chen et al, 2007).  In an atypical response, mice hind limbs were clenched 
together and held either away from or near the body. The categorical tail suspension data 
for mice of different genotypes were binned in three-month intervals and statistically 
compared using the Fisher’s exact test (two-tailed distribution). 
The accelerating rotarod test utilized an instrument (IITC Life Science, model# 755) 
programmed to start at 5 RPM, ramp to 40 RPM over 60 seconds, and then maintain 40 
RPM speed for a total time of three minutes (Sabblah et al, 2018). The elapsed time until 
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the mouse fell off the rotating rod was automatically collected with the Series 8 software 
provided with the instrument (Hennis et al, 2013).  Each mouse performed three 
successive runs and these 3 readings were averaged for each test day. Each test mouse’s 
averaged rotarod reading from test days was averaged again for 3-month bins. The wild-
type and H304R/+ binned rotarod datasets were statistically compared for 3-month bin 
using the two-tailed Student’s t-test (Sabblah et al, 2018).  
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Figure 11 Parameters for the motor coordination assay 
After a series of trials with different parameters, the optimized conditions for our motor 
coordination assay on the rotarod were as follows: a speed of 5 to 40 rpm with a ramp 
time of 60 seconds over a total duration of 180 seconds.  
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The limb muscular strength of mice was measured with a digital grip strength instrument 
(BIOSEB Research Instruments, model# BIO-GS3). Each test mouse was placed on the 
steel grid attached to the instrument and the grip strength reading was collected as per the 
manufacturer’s protocol. The manufacturer’s RSIC software recorded the maximum force 
(in grams) exerted by the mouse on the steel grid. The grip strength in the front two limbs 
and all four limbs were measured for each test mouse (Mandillo et al, 2008). Mice could 
not grip the instrument solely with hind limbs, preventing the direct assessment of hind 
limb strength.  All the grip strength measurements were taken in quadruplicates and the 4 
reading were averaged on each test day. Each test mouse’s averaged grip data from test 
days was averaged for 3-month bins. The wild-type and H304R/+ binned grip datasets 
were statistically compared using the two-tailed Student’s t-test.  
2.4 Tissue Preparation 
Animals were anesthetized via intraperitoneal injection with SomnaSol ™ (7.5 mg/kg, 
Henry Schein, Dublin, OH, USA). Cardiac perfusion was performed using 25 mls of 
0.9% Saline (Hospira, Lake Forest, IL, USA) and then 4% paraformaldehyde (Sigma-
Aldrich, ST Louis MO, USA). Gastrocnemius muscles were carefully dissected from 
animals and kept in 4% paraformaldehyde (Dequen et al,2008). The muscles were 
transferred into 30% sucrose for cryopreservation overnight at 4oC.  Muscles were 
embedded in OCT Compound in plastic cryomolds (Sakura Fine Tek, Torrance, CA, 
USA) and stored at -80 oC until ready for sectioning. 20 µm sections were obtained from 
muscles using a cryostat (Leica CM1850) and attached to Superfrost Plus slides (Fisher 
Scientific, Pittsburgh, PA).  Fixation was done by immersing slides in acetone for 20 
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mins at room temperature. The slides were then stored at -20 oC until ready for staining 
and imaging (Sabblah et al, 2018). 
2.5 Immunohistochemistry and Imaging 
For neuromuscular junction analysis cryosections were first washed with PBS for 10 
minutes each to clear out the OCT. The edges of the sections were marked with a PAP 
pen to restrict the staining solution. Sections were then permeabilized for 10 mins with 
0.5% Triton X100 and blocked for up to three hours in 5% bovine serum albumin and 
goat serum with 0.1% TritonX100 in PBS at room temperature. Staining was done in a 
humidified chamber with antibodies against neurofilament (2H3, DSHB and chicken NF-
H, EMD Millipore). The sections were washed three times with block solution for a 
duration of 10 mins each. Alpha subunits of Acetylcholine receptors (AChRs) and 
neurofilament were stained with the appropriate Alexa Fluor secondary antibodies (goat 
anti-mouse 546, goat anti-chicken, 546, 488 alpha-bungarotoxin, Life Technologies, 
Eugene, OR, USA).  Two washes were first done with block solution for 10 minutes each 
and then two final washes with PBS for 10 minutes each time. The sections were 
mounted in antifade reagent containing DAPI (Life Technologies, Eugene, OR, USA) to 
stain the nuclei. Images of neuromuscular junctions were obtained using a Zeiss LSM 
710 Confocal microscope (Sabblah et al, 2018). 
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Figure 12 Determination of Innervation using Image J Software 
A schematic representation of the steps involved in determining innervation at the NMJ 
as well as the appropriate plug-in to use 
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2.6 Analysis of NMJ Architecture 
Stacks obtained from confocal imaging were processed further using ImageJ for analysis 
of innervation patterns and acetylcholine receptor (AChR) architecture (Figure 12).  
The 3D Viewer plug-in was used in determining innervation at the NMJs (Schmid et al, 
2010). The respective channels corresponding to neurofilament and AChR staining are 
merged prior to applying the plug-in. The plugin enables rotation of the reconstructed 
confocal image to examine the degree of innervation from different angles, this is useful 
to find out whether the nerve occupies the post-synaptic region or not.  
The 3D object counter was used to measure the volume and surface area of the AChRs 
(Figure 14). The image is prepared by ‘smoothening’ to reduce noise and applying a 
binary mask so that the images appear black against a white background. The threshold is 
then be set to exclude objects that are outside the region of interest.  
We utilized another set of plug-ins; Skeletonize 2D/3D and Analyze Skeleton 2D/3D to 
generate a single line version of the image and evaluate different indicators of the 
resulting structure (Figure 13, Arganda-Carreras et al, 2010). These indicators constitute 
the complexity parameters used in characterizing the AChR’s (Table 1). We obtained 
counts of branches, junctions, triple points, end-point voxels and slab voxels. The 
program also calculates the average branch length, maximum branch length and longest 
shortest path. The student’s T-test was used to determine the statistical significance of the 
data obtained. 
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Figure 13 How to analyze skeletons of the NMJ structure 
Diagram showing how to process confocal images into skeletonized images and obtain 
analyses that characterize the complexity and morphology of the NMJ 
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Figure 14 How to measure surface area and volume of AChRs 
The schematic outlines how to process image stacks from the confocal image to obtain a 
calculation of the surface area and volume.  
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Table 1 List of Complexity Parameters Used in Characterizing Neuromuscular 
Junction Architecture 
 
Parameter Definition 
 Branches The number of elongated segments in the skeletonized NMJ that link a junction point to 
the nearest junction or end point. 
Junctions The number of vertices in the skeletonized NMJ that connect two or more branches. 
Triple points The number of vertices in the skeletonized NMJ that connect three branches. 
Voxels The three-dimensional building blocks (“pixels”) in the 3D skeletonized NMJ. 
Endpoint voxels The number of voxels with only one neighbor voxel. 
Slab voxels The number of voxels with two neighbor voxels. 
Junction voxels The number of voxels with more than two neighbor voxels. 
Average branch length The mean branch length of all branches in the skeletonized NMJ. 
Maximum branch 
length 
The length of the longest branch in the skeletonized NMJ. 
Longest shortest path The shortest path distances between all possible endpoint pairs in the skeletonized NMJ 
are determined. The longest of these shortest path distances is then identified. 
Area to Volume Ratio The surface area to volume ratio of the NMJ. 
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2.7 Determination of Nuclear Distribution 
To analyze nuclei morphology at the NMJ, we processed confocal images with Image J 
software. Confocal images in the ‘Maximum Intensity Projection’ format were utilized 
for length and width measurements of the nuclei. First the area around the NMJ was 
delineated to help identify nuclei associated with the synapse for analysis. This was done 
with the help of the MorphoLibJ plug-in (Legland et al, 2016). ‘Morphological filters’ 
are applied to images of the AChRs using a disk to set a 38-pixel dilation for all images 
to capture associated nuclei, any nuclei that has more than 50% of its area within this 
region is counted. This is further confirmed by rotating the image in 3D. Nuclei that do 
not meet this criterion and that fall outside the dilated region are excluded from the 
analysis. After the background is adjusted on the image, the wand tool is used to mark out 
the boundaries of the dilated region (Figure 15). This region is saved using the ROI 
manager, and later applied to images of the nuclei to obtain the relevant nucleus for 
analysis. The line drawing tool was used to mark out the length and width of the nucleus 
which were perpendicular to each other and drawn from the farthest points of the nuclei 
in each direction. The longest distance was considered the length and the shortest the 
width, the ellipticity value is obtained by dividing the width by the length. 
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Figure 15 Illustration of analysis on sub-synaptic nuclei 
A 10µm radius is marked on confocal images of the NMJ to include relevant sub-
synaptic nuclei for the analysis. The length and width of all nuclei that fall within this 
radius are determined and the ellipticity calculated. 
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CHAPTER 3:BEHAVIORAL CHARACTERIZATION OF CMT2O 
MOUSE MODELS 
3.1 Introduction 
A lot of what is known about dynein function has come from studies in different systems, 
such as yeast, fungi, fruit flies and mice (Wickstead and Gull, 2007, Moore et al, 2009, 
Egan et al, 2012). Knockdown studies in mice provided strong evidence showing that 
dynein is imperative in supporting life (Harada et al, 1998). The use of animal models of 
disease however requires first, the investigation and identification of phenotypes related 
to the disease. The dynein mouse models Loa, Cra, and Swl have been well characterized 
with motor and sensory abnormalities (Schiavo et al, 2013).  
The first characterized human mutation in the dynein heavy chain was found to cause 
CMT disease, specifically type 2O. (Weedon et al, 2011). We therefore made a knock-in 
mouse with the corresponding H304R mutation that causes CMT2O to study the disease 
and obtain further insight into how dynein function is altered. CMT2O patients usually 
develop muscle weakness, gait problems and delayed milestones (Weedon et al,2011). 
Based on the presentation of the disease in humans, a good mouse model should have 
similar motor phenotypes. To find out if our CMT2O mouse models had a phenotype 
reminiscent of CMT disease, we conducted a longitudinal assessment of the locomotor 
skills of wild-type and mutant mice bearing the H304R mutation. We employed 3 assays 
namely; the tail suspension assay, grip strength measurements and motor coordination 
assessment. These assays have been widely used to determine neuromuscular 
impairments in various animal models of disease (Brooks and Dunnett, 2009). Dynein 
mouse models (loa, cra, swl) and some CMT2 mouse models (CMT2D, CMT2E) have 
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been assessed for their locomotor properties via the tail suspension and motor 
coordination on the rotarod (Rogers et al, 2001, Dequen et al, 2010, Shen et al, 2011). 
The choice of these motor behavioral assays gives us a basis for comparison of results 
with studies involving other CMT2 and dynein mouse models. 
3.2 Results 
3.2.1 Investigation of defects in the heterozygous mouse 
We generated a heterozygous knock-in mouse line that carries the corresponding H304R 
mutation in the mouse cytoplasmic dynein gene.  We characterized potential loco-motor 
phenotypes by examining both male and female littermate wild-type and H304R/+ mice 
in a 12-month longitudinal study. Over the time points analyzed, H304R/+ mice had no 
obvious physical or cage behavioral phenotypes that could be distinguished by eye from 
littermate wild-type animals. We tracked the general health of those animals and saw no 
obvious health differences in the animals outside of a modest weight gain in 3-month old 
female H304R/+ mice that disappeared as the mice aged 
3.2.1.1 General observations and cage behavior 
All mice regardless of genotype were bred using the same scheme and housed under 
standard conditions with unlimited access to food, water and cage enrichment. For 
purposes of our behavioral study, male and female mice were separated into different 
cages after weaning. All mice were periodically observed to assess their general well-
being or to pick out signs of ill-health. Some of the signs we looked out for were; the 
level of activity, condition of the fur, skin and eyes, locomotion, posture and examination 
of cage litter for signs of fecal and urine elimination. This exercise is particularly critical 
for a novel mutation, because we do not know how the introduction of the transgene 
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affects the behavior of the litter. We recorded all health concerns encountered and the 
response to treatment as well. After comparing the genotypes of animals with health 
concerns, we ruled out the contribution of the H304R dynein heavy chain mutation. We 
tracked the weights of the mice and found no significant genotype –specific effect on 
weight change over the duration of the study. 
3.2.1.2 Picking out the right tools to determine phenotype 
We started out by analyzing behavioral phenotypes making use of some well-known 
assays, namely; wire mesh, the hanging rod both of which test for locomotion and 
balance (Figure 16). For gait analysis we painted the feet of the animals; utilizing two 
different colors to differentiate front paws from hind paws (Crawley,2008). Although 
these assays were suitable for other phenotypes, with the exception of the tail suspension 
assay, we obtained very little reproducible results with our mice. We resorted to the use 
testing methods that required minimal tester involvement in our bid to find out whether 
the H304R mutation had any phenotype based on published work on dynein and CMT2 
mouse models (Rogers et al, 2001 Bogdanik et al,2013, Zhang et al,2014). We therefore 
settled on the rotarod and grip strength meter which came with software packages to 
automatically record data for analysis. The use of these equipment resulted in more 
efficient work as it eliminated a lot of optimization and troubleshooting time. Testers 
were blind to the genotype of the mice, and they carried out initial trials with the mice 
before actual performance measurements. The rotarod required testing out different 
parameters to determine the most suitable testing condition. 
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Figure 16 Mouse footprints assay 
A sample of the output from the footprint assay with fore and hind paws distinguished by 
different colors and showing 2 patterns of footsteps.  A) Regular footprints from a mouse 
that took normal steps. B). Irregular pattern of footprints obtained from a mouse that 
could be jogging or running. 
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3.2.1.3 H304R/+ mutant mice show an altered tail suspension reflex  
 
Wild-type mice generally display a characteristic tail suspension reflex of splayed hind 
limbs held away from their body when suspended by their tails. Several studies of Loa/+, 
Cra/+ and Swl/+ mice pointed out that those mice display an atypical phenotype of 
clenching their hind limbs when suspended by their tails. We performed a similar tail 
suspension assay at successive 3-month time points and found that the majority of male 
and female wild-type and H304R/+ mice displayed the normal splayed tail suspension 
reflex phenotype at each time. However, both male and female H304R/+ mice showed a 
significant increase (p <0.05) in atypical tail suspension responses relative to wild-type at 
9 and 12 months (Figure 17A). These data suggest that the H304R/+mice have a hind 
limb defect but that the defect is less pronounced than the phenotypes in Loa/+, Cra/+, 
and Swl/+ mice as only a subset of H304R/+ mice display the atypical response. 
3.2.1.4 H304R/+ mutant mice have reduced muscular strength 
 
We next analyzed the limb muscular strength in our mice using a standard grip strength 
assay.  Male H304R/+ mice exhibited significant weakness in all limb grip strength 
relative to wild-type male mice at all ages examined.  To further tease apart the 
contribution of front and hind limbs to this phenotype, we examined the strength of the 
front limbs solely. We found that there was a significant, progressive weakness in front 
limb grip strength of male H304R/+ mice relative to wild-type mice that occurred in the 
later 9 and 12-month time points (p< 0.05) (Figure 17B).  These data suggest that the 
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mice have reduced function in the hind limbs at an early age, and that front limb 
weakness progresses as the mice age.   
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Figure 17 Motor performance test results 
Behavioral phenotypes of H304R/+ mice. (A)The atypical tail suspension reflex was 
scored and counted for each test mouse per 3-month long time intervals and the scores 
were statistically compared between the wild-type and H304R/+ mice groups using 
Fisher’s Exact Test (two-tailed distribution, p<0.05).  (B)The grip strength was measured 
in the all limbs of the male and female mice, and in the front limbs of the male and 
female mice. The data was statistically compared between wild-type (filled circles) and 
the H304R/+ (empty circles) mice groups using the t-test (two-tailed distribution, *= 
p<0.05). (C)The rotarod performance was measured for both the male and female mice. 
Grip and rotarod readings from each test mouse was then averaged per 3-month long time 
intervals respectively. The data was statistically compared between wild-type (filled 
circles) and the H304R/+ (empty circles) mice groups using the t-test (two-tailed 
distribution, *= p<0.05). 
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When we examined female mice, we found subtle defects in the combined grip strength 
at 6 and 9 months of age for H304R/+ females, but no defect in front limb grip strength at 
any age. The grip strength data is consistent with our tail suspension data, showing that 
there is a general trend of reduced neuromuscular function in H304R/+ animals as they 
age. 
3.2.1.5 H304R/+ mutant mice have motor coordination defects 
 
The rotarod test is a performance-based test for the evaluation of muscular endurance, 
motor coordination and balance in mice. We utilized an accelerating profile where the 
mice were tested for their ability to adjust to increasing revolutions during a ramp time 
followed by a consistent speed for the remainder of the assay. When we examined the 
ability of wild-type and H304R/+ littermates to perform this assay, we found that 
individual animals of a particular genotype could exhibit a wide range of abilities.  
However, as a group, H304R/+ males had reduced rotarod performance at 3, 6, and 9-
month time points (Figure 17C).  Female H304R/+ mice only displayed a significant 
difference in rotarod performance at the earliest time point examined.  This difference 
disappeared as the female mice aged.  Loa/+ mice had been previously characterized with 
the rotarod test and showed similar defects. 
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3.2.2 Characterization of the homozygous mouse model 
The H306R mutation originally discovered in the cytoplasmic dynein heavy chain in 
humans occurs as an autosomal dominant heterozygous genetic defect (Weedon et 
al,2011). Heterozygous mutations in loa, cra, swl mice have provided some clues about 
how a mutation in dynein can lead to neurological dysfunction. Homozygous mice with 
the loa, cra, swl mutation result in early lethality and therefore a study of the progression 
of the disease and the effects on the motor in these disease models hasn’t been possible. 
A homozygous dynein mouse model that is able survive long enough for a longitudinal 
assessment will fill that gap. Our H304R/R homozygous mouse fortunately addresses 
that, with homozygous animals able to survive beyond the first year of life. Of particular 
interest was the discovery of homozygous dynein in an individual from a genetic screen 
involving 30 subjects (Scoto et al,2015). This individual with the homozygous mutation 
had arthrogryposis from birth, cognitive impairment and ADHD (attention deficit 
hyperactive disorder). These features were more severe than what the heterozygous 
parents had. One parent had muscular weakness and denervation in the lower limbs 
whereas the other showed no obvious symptoms.  
Generally, the homozygous mice had deficits at all time points looked at. Furthermore, 
the gender differences that were a feature of the heterozygous mice, (ie. females having a 
weaker phenotype) appear to have diminished in the homozygous mice.  A study in 
Germany looked at gender differences among CMT patients and gender was found to 
play a role in the incidence of muscle force in the lower limbs, with men being affected 
more than women (Wozniak et al, 2015). This finding agrees with the pattern observed in 
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our behavioral assays in heterozygotes, where female mice generally had a weaker 
phenotype compared to males. 
 
3.2.2.1 H304R/R mice survive after birth 
After obtaining the approval to breed homozygous mutants from two heterozygous 
parents, we were initially curious in finding out whether the homozygous mice will 
survive after birth and if so, how long their life span will be. The homozygous mutation is 
lethal in other dynein mutants, with mice surviving only a few days after birth. H304R/R 
homozygous mice survive up to 2 years after birth and as such can undergo a longitudinal 
assessment of phenotypes similar to what was done in heterozygous mice (Sabblah et al, 
2018). H304R/R homozygous mice can be differentiated from wild-type and even 
heterozygotes by the 30th day after birth. Some of the mice are often smaller and develop 
a characteristic high steppage gait. 
3.2.2.2 H304R/R homozygous mice have severe neurological impairments 
We carried out motor performance assays, namely tail suspension, muscle strength and 
motor coordination in homozygous mice to characterize their phenotype.  We tested both 
male and female mice at 5 timepoints altogether:1 month, 3 months, 6 months, 9 months 
and 12 months. We were anticipating a harsher effect of the mutation on neuromuscular 
performance, however, we didn’t know what to expect in terms of progression and how 
the general activity of the mice will be affected and whether gender differences will be 
seen, as was the case with heterozygotes.  
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Our neurological assessment of mice based on hind limb clasping in the tail suspension 
assay confirmed our expectations as homozygous mice presented a more robust 
phenotype (Figure 18). About 60% of homozygous animals clenched their hind limbs 
and often writhed in an attempt to assume a more comfortable posture (Figure 19A). This 
peculiar behavior often made the homozygous distinguishable from the other genotypes.  
 
3.2.2.3 Homozygous mice show a pronounced motor phenotype 
Atrophy of the muscle, weakness and gait problems are well-documented in CMT2 and 
peripheral neuropathies in general. Other dynein mouse models also presented with 
muscular issues as well, therefore it was only a question of how severely the H304R/R 
homozygous model will be affected. We first evaluated muscle strength in all limbs of 
the mice on the grip meter. Lower values were consistently recorded for homozygous 
mice throughout the study. In female homozygous mice the deficiency in the muscle was 
seen earlier at 3-months whereas in heterozygotes differences occurred at 6 months 
(Figure 25). To tease out the contribution of each set of limbs to the phenotype, we took 
grip strength readings in the fore limbs. We found reduced muscular strength in forelimbs 
of mice meaning that in the homozygous mice both fore and hind limbs are targets of the 
peripheral neuropathy. Both males and females suffered in the fore and hind limbs.  
Motor coordination discrepancies were also observed consistently at all time points in 
both male and female mice. Homozygous mice on the average, fell of the rotarod before 
the 60 second ramp time set on the instrument (Figure 11). Although the motor 
phenotypes didn’t progressively worsen in homozygous mice over time, the performance 
of mice on the assays reveals the severity of the homozygous mutation. 
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Figure 18 Hind limb posture in mice on the tail suspension assay 
Scores are given based on widely apart animal hold their hind limbs apart. Wild-type 
mice are typically awarded a score of 3 the highest score, majority of the heterozygous 
mice score 2 displaying mostly 2 forms of partial limb clasping. Homozygotes largely 
obtain a score of 1 as they are unable to keep their feet apart and have them clutched
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Figure 19 Phenotypic assessment of homozygous mice 
Hind limb posture assessed in mice (A, B). Muscle strength in all limbs was measured 
with the help of a grip meter (C, D). Fore limb strength alone was also measured (E, F). 
Motor coordination based on the latency of the animal to fall was determined on the 
rotarod (G, H)  
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3.3 Discussion 
3.3.1 Assessment of H304R Phenotype 
To gain understanding of the onset and progression of axonal CMT as well as the role of 
cytoplasmic dynein in cellular neuropathy, we have generated and initially characterized 
a knock-in mouse carrying the H304R mutation in the cytoplasmic dynein heavy chain. 
This mutation corresponds exactly to the human H306R DHC mutation that results in 
CMT2O (Weedon et al,2011). We examined both male and female H304R/+ mouse 
cohorts in a 12-month longitudinal assessment study to determine if the mutant DHC 
allele causes dominant locomotor deficits similar to those exhibited by individuals with 
CMT2; we also assessed whether H304R/+ male mice have neuromuscular pathologies. 
H304R/+ male mice exhibit phenotypes that would be expected for a mouse model of 
CMT disease.  The mice displayed muscle weakness, loss of motor coordination and 
atypical tail suspension reflexes compared to littermate controls.  In addition, although 
our assay could not distinguish hind limb muscle strength directly, the progression of 
limb weakness from early onset “all limb” only to significant weakness in the forelimbs 
specifically at the later time points strongly suggests that the mouse disease pathology is 
following the progression of symptoms in humans from difficulty walking to progressive 
inability to use hands effectively. 
Interestingly, we found differences in severity of phenotypes based on the sex of the 
animal, with female animals having weaker phenotypes overall compared to male 
counterparts when measuring grip strength and motor coordination but similar atypical 
tail suspension reflexes. We believe that our female H304R/+ mice exhibit milder CMT 
characteristics that will require more sensitive locomotor assays to distinguish. The initial 
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study of human CMT Type 2O characterized 8 males and 5 females in detail, with no 
obvious differences between the sexes being noted (Weedon et al,2011). It is possible that 
our observed difference in expressivity of H304R/+ between males and females is due to 
specific sexual differences in the characteristics of mice; it will be extremely interesting 
to determine if the variation in expressivity occurs at the cellular level. Especially when 
sex differences have been observed among CMT patients in a study looking into the 
severity of the disease (Wozniack et al, 2015). 
3.3.2 Phenotypic features of the H304R/R homozygous mouse 
The phenotypes observed in our CMT2O homozygous mice were expectedly more severe 
than heterozygous animals, but there is also a difference in the way the homozygotes are 
affected.  Homozygous mice are distinguishable from heterozygotes in appearance, they 
generally weigh less and are smaller and develop a high steppage gait at about 14 days 
after birth. Our behavior data shows that the predominant motor phenotype due to the 
H304R mutation in the dynein heavy chain is more pronounced in the homozygotes as it 
develops earlier than in the heterozygotes in some cases. Significantly the sex differences 
in the phenotype were eliminated as the both males and females recorded comparable 
behavioral deficits. For instance, there were no deficits recorded in the heterozygous 
female fore limb strength, however the homozygotes displayed fore limb weakness at all 
the time points looked at compared to male mice (Figure 19). Although the reason for the 
minimized effect of the CMT-related phenotype is not known in females, it is obvious the 
homozygous mutant protein and therefore dynein is affected strongly enough to produce 
a robust phenotype in males. Another factor that is worth noting is in terms of the 
progression of the disease is that the ability of the animals to recover is lost with the 
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homozygous mutation. Motor coordination is restored in male mice by the 12th month 
and in female mice by the 6th month in heterozygotes, in the homozygous however, all 
time points are affected. Simultaneously there appears to be the early development of a 
motor phenotype in the homozygous animals, this is also corroborated in the data on 
NMJ analysis. 
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CHAPTER 4:HISTOLOGICAL ANALYSIS OF MUSCLE 
FUNCTION 
4.1 Introduction 
Cytoplasmic dynein has specialized roles in specific cell types in as much as there are 
general functions in many cells. This is perhaps one of the factors underlying the wide 
range of symptoms observed in living organisms when there is mutation in the 
cytoplasmic dynein gene. A typical investigation into a dynein therefore should include 
the isolation and investigation of different subcellular components for further analysis. 
Different studies have shown how dynein mutations can affect some cellular targets and 
not others (Dupuis et al, 2009, Braunstein et al, 2010, Eschbach et al, 2011). The loa, cra 
and swl dynein mutations have been examined at the tissue level for neuromuscular 
abnormalities. The neuromuscular junction was found to be affected by perturbations in 
dynein function in the cra heterozygous mice (Courchesne et al, 2011). The link between 
dynein and neuromuscular junction dysmorphology could be due to dynein activity in 
motor nerves (LaMonte et al, 2002, Levy and Holzbaur, 2006). 
The results of our initial loco-motor studies, altered behavior in tail suspension, grip 
strength, and rotarod assays, suggested to us that there might be a physical defect in the 
neuromuscular system in the mutant H304R/+ mice.  To examine this possibility directly, 
we characterized the sarcomere and neuromuscular organization of the gastrocnemius 
lower limb muscle from male wild-type and mutant mice.  We chose to examine 
specifically male mice, as they exhibited more significant motor behavior skills defects 
than female mice. Fixed gastrocnemius muscle tissue slices were labeled with antibodies 
for key components of those structures and imaged using standard confocal microscopy. 
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Our survey of 9 and 12-month tissue showed no defect in the number or overall 
organization of sarcomeres between wild-type and H304R/+ mutant mice 
 
4.2 Results 
4.2.1 Investigation of Defects in the heterozygous mouse 
We tested the possibility of the defects in mice arising from an improperly assembled 
motor protein by comparing the levels of dynein in the brains of wild-type to mutant 
(H304R/+) mice. Quantification done on the immunoblot showed no difference in the 
levels of the intermediate chain of dynein (Figure 18). We were unable to specifically 
examine dynein heavy chain protein levels in the brain samples due to incomplete 
transfer of the approximately 4700 amino acid protein from the gel to the membrane. 
The results of our initial loco-motor studies, altered behavior in tail suspension, grip 
strength, and rotarod assays, suggested to us that there might be a physical defect in the 
neuromuscular system in the mutant H304R/+ mice.  To examine this possibility directly, 
we characterized the sarcomere and neuromuscular organization of the gastrocnemius 
lower limb muscle from male wild-type and mutant mice.  We chose to examine 
specifically male mice, as they exhibited more significant motor behavior skills defects 
than female mice. Fixed gastrocnemius muscle tissue slices were labeled with antibodies 
for key components of those structures and imaged using standard confocal microscopy. 
We examined sarcomere organization by staining the Z-line with alpha-actinin (Figure 
19).  We saw no qualitative difference between images of wild-type and H304R/+ mutant 
mice.  We also measured the mean sarcomere distance in the muscles and saw no 
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significant difference (p= 0.08) between those of wild-type (2.22 µm sarcomere length 
from 11 muscle fibers and 689 individual sarcomeres) and H304R/+ (2.20 µm sarcomere 
length from 11 muscle fibers and 702 individual sarcomeres). 
4.2.1.1 Determining complexity in the NMJ architecture 
Complexity is a classical feature of the mature neuromuscular junction and resulting 
changes in architecture could also be valuable in predicting the involvement of some kind 
of neuromuscular pathology. It is therefore important to be able to capture and quantify 
the various changes that could occur in the event of an underlying disease in the course of 
development. NMJ complexity in simple terms is descried as a ‘pretzel-like’ structure 
after a series of transformations have occurred from the initial ‘cookie’ structure or 
plaque early in development. In situations where the changes are subtle, it is important to 
have analytical tools that are both sensitive enough and at the same time reproducible. 
Complexity has been previously defined based on different ways of studying 
neuromuscular junctions (Courchesne et al, 2011, Sleigh et al,2014). We used plug-ins 
from ImageJ software to determine NMJ complexity based on 10 parameters (Table1). 
The advantage is that minor changes over time can be noticed as was the case for early 
time points in our longitudinal study of the H304R mutation in the dynein heavy chain.  
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Figure 20 Dynein expression in brain of mice 
Protein levels of the dynein intermediate chain from brain tissue high speed supernatant 
of both wild-type and heterozygous mice. Statistical analysis using the student’s t-test, 
two-tailed distribution, showed no significant difference in protein expression (p=0.23) 
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Figure 21 Sarcomere organization in heterozygous mice 
A) Gastrocnemius muscles were stained with α-actinin to show the Z-line (in green) in 
the sarcomeres of wild type and mutant H304R/+ mice. B) No differences were observed 
in the length of the sarcomere in wild type and H304R/+ muscle tissue 
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Figure 22 General morphology of NMJs in mice 
AChRs from wild-type and heterozygous (H304R/+) mice at 9 and 12 months were 
stained to assess the morphology of the NMJ. Wild-type muscles had more of the typical 
complex morphology compared to mutant heterozygous mice. 
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4.2.1.2 Neuromuscular junction dysmorphology 
We labeled 9 and 12-month tissue slices with fluorescent alpha-bungarotoxin to examine 
the NMJs of wild-type and H304R/+ mice. NMJs from wild-type mice displayed the classic 
pretzel shaped morphology with a highly branched complex appearance (Sanes and 
Lichtman, 2001).  However, NMJs from H304R/+ animals presented a mixture of NMJ 
morphologies ranging from the classic morphology to those with obvious defects in size, 
branches, and complexity. 
To more thoroughly characterize the NMJ defect, gastrocnemius tissue samples were 
analyzed from both wild-type and mutant H304R/+ mice from 1, 3, 6, 9, and 12-month old 
male animals. Qualitatively, we saw abnormal NMJ complexity/morphology in 1-month 
H304R/+ tissue and no discernable phenotype in 3-month H304R/+ tissue.  This was 
followed by an increasing percentage of NMJs with more obvious defective morphologies 
in the 6, 9, and 12-month time-points.  However, not all NMJs were abnormal in the 
H304R/+ mice: there was a range of NMJ morphologies present at all time points.  We 
found that an individual mouse could display a mixture of normal and abnormal NMJ 
morphologies and that there was a range of abnormalities present in the NMJs 
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Figure 23 Altered neuromuscular junction morphology  
Confocal images of representative NMJs stained with neurofilament (red) and alpha-
bungarotoxin (green) at different time points. A: 1 month, B: 3 months, C: 6 months, D: 9 
months, E: 12 months. Graphs show twelve parameters that were examined for the NMJ 
architecture in wild-type and H304R/+ animals, displayed as the H304R/+ percentage of 
the wild type value, grey bars represent H304R/+, black dotted line is wild-type. 
Statistically significant differences between wild type and H304R/+ values are indicated 
by * (two-tailed distribution, p<0.05). Scale bar =20µm    
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To quantitatively characterize the defects in NMJ morphology we processed image stacks 
of AChR fluorescence as described in Materials and Methods.  Our analysis identified 
several interesting features that occur as the mice reach and pass through adulthood.   At 
one month of age, H304R/+ NMJs have statistically significant defects in six of the 
parameters examined (Figure 21A).  Notably, the one-month H304R/+ NMJs have fewer 
branches as seen by the branch, junction voxel, and triple point parameters. Furthermore, 
the branches present are longer than those in wild-type animals.   Finally, there is a 
reduction in the surface area to volume ratio of the entire NMJ.  These characteristics can 
be seen in Figure 21A as these representative H304R/+ NMJs show fewer longer branches 
present.  At three months of age the overall morphology of H304R/+ and wild-type NMJs 
were indistinguishable and the quantitative analysis was unable to identify any parameters 
with statistically significant differences.   
At six months of age we observed a small subset of H304R/+ NMJs that appeared less 
complex than the typical wild-type NMJ.  However, these were only a fraction of the 
overall NMJs and the surface area/volume ratio was only parameter with a statistically 
significant difference between genotypes (Figure 21C).  At the 9-month time point, there 
were a sizeable percentage of H304R/+ NMJs with obvious morphological defects (Figure 
21D).  Our analysis showed that there was a reduction in most of the quantitative 
parameters we measured, and that reduction was statistically significant for four of the 
parameters in H304R/+ mice compared to wild-type littermate control mice (Table 1).We 
found the decrease in the percentage of NMJs that were innervated to be especially 
interesting as it may indicate that some form of degeneration may have occurred in these 
older NMJs. 
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The NMJs of 12-month old H304R/+ mice had severe defects from both qualitative and 
quantitative assessments.   Many of the H304R/+ NMJs had a wider junction diameter with 
a notable reduction in the number of branches present (Figure 21E).  Our quantitative 
analysis of H304R/+ NMJs identified ten parameters with statistically significant decreases 
relative to age matched wild-type NMJs (Table 1).  These differences are indicative of the 
gross abnormalities present in many of the H304R/+ NMJs.   The percentage of NMJs that 
were innervated correctly was dramatically reduced in the H304R/+ NMJs at 12 months 
similar to the 9-month time point. 
 
4.2.2 Analysis of Defects in the CMT2O Homozygous Mouse Model 
To delve deeper into how a point mutation (H304R) in the dynein heavy chain leads to 
dynein dysfunction and result in CMT disease-related phenotypes in our mouse model, 
we bred two heterozygotes to generate homozygous mice with the mutation in both 
dynein heavy chain genes. We assessed the phenotype of the homozygous mice through 
our behavioral assays and discovered stronger phenotypes than previously noticed in 
heterozygous mice and therefore a wider difference when compared to wild-type versus 
heterozygotes compared to wild-type. We were interested in whether neuromuscular 
abnormalities in the tissue of homozygous mice would similarly be worse than 
heterozygotes. Firstly, we examined sarcomere organization in 12-month-old male 
homozygous mice and compared the results to both age-matched wild-type and 
heterozygous mice. We chose 12-month old animals because they represent the stage at 
which mice show with the most drastic effect from the H304R dynein mutation. 
Sarcomere measurements were taken based on alpha-actinin staining of Z-lines in muscle 
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fibers of gastrocnemius muscles. There were no obvious genotype-specific differences 
judging from the arrangement of Z-lines in muscle fibers from confocal images (Figure 
24A).  
However, we noticed a slight reduction in sarcomere lengths in homozygous mice with a 
mean sarcomere length of 2.11µm (Figure 24B). This value represents a 5% decrease 
compared to wild-type (2.22µm) and a 4% decrease compared to heterozygote mean 
sarcomere length (2.20µm). This difference in sarcomere length between wild-type mice 
and mutants was statistically significant (p<0.05). More experiments are needed to 
determine the reason for the change in sarcomere length, and if it is a direct or indirect 
result of dynein dysfunction. Sarcomere organization in the fruit fly, was found to occur 
after nuclear placement in the muscle fibers (Auld and Folker, 2016). Should this be true 
in mice as well, it could partly explain why sarcomere lengths in homozygous mice may 
be slightly altered. This is because our preliminary assessment of myonuclear positioning 
of subsynaptic nuclei suggests some discrepancies in homozygous mice at the 12-month 
time point (Figure 29). 
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Figure 24 Sarcomere organization in homozygous mice 
a) Representative images of sarcomeres in gastrocnemius muscles of 12-month-old mice 
for each genotype b) graph showing mean sarcomere lengths in muscle fibers for each 
genotype. The mean values were obtained from 682 wild-type,702 H304R/+ and 744 
H304R/R individual sarcomeres 
A 
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Figure 25 Comparison of NMJ morphology across genotypes  
Representative images of AChRs for each genotype based on alpha bungarotoxin staining 
at 12 months. Homozygous NMJs were clearly distinguishable from wild-type and even 
heterozygotes by being less branched and less connected branches. They also displayed 
fragmentation and had more regions of low fluorescent intensity. Heterozygous NMJs 
compared to wild-type were generally less complex. 
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4.2.2.1 H304R/R homozygous mice display more defects in motor endplate architecture 
Heterozygous mice showed aberrations in the organization of the NMJ as well as 
innervation defects at 9 and 12 months compared to wild-type mice. We compared the 
general morphology of NMJs from gastrocnemius muscles of homozygous mice to wild 
type and heterozygotes and we saw more severe abnormalities (Figure 23). The NMJs 
were generally disconnected and unlike the heterozygote muscles, there were more 
fragmented NMJs. Homozygous mice displayed very low NMJ complexity and in some 
instances had regions of low receptor density. They appeared smaller in size and quite a 
number of them had no nerves at all. We proceeded with a longitudinal assessment of 
NMJ innervation and architecture at 1 month. 3 months, 6 months, 9 months and 12 
months. In terms of innervation, H304R/R mice were notably different from H304R/+ 
mice by showing consistent deficits at all time points from 1 month to 12 months. The 
number of NMJs that were innervated was higher at 9 months and 12 months compared 
to wild type but also lower than that of heterozygous mice. 
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Figure 26 Abnormal NMJ architecture in gastrocnemius muscles of H304R/R mice 
Confocal images of representative NMJs stained with neurofilament (red) and alpha-
bungarotoxin (green) at different time points. A: 1 month, B: 3 months, C: 6 months, D: 9 
months, E: 12 months. Graphs show twelve parameters that were examined for the NMJ 
architecture in wild-type and H304R/+ and H304R/R animals as the percentage of the 
wild type value. Grey bars represent H304R/+, striped bars are H304R/R, red dotted line 
is wild-type. Statistically significant differences between wild type and H304R/+ shown 
by * and differences between wild type and H304R/R values are indicated by * (two-
tailed distribution, p<0.05). Scale bar =20µm
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Table 2 Morphological assessment of wild-type and mutant NMJs 
 
                              
The number of AChRs analyzed (n), number of animals per genotype (N) and mean values (± standard 
deviation) of different parameters assessing NMJ complexity. Innervation is shown as the percent of examined 
NMJs with nerves that occupy more than half of the receptor volume. SA / VOL: surface area to volume ratio. 
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The dysmorphology of NMJ architecture is seen more strongly at 1 month than in 
H304R/+ with differences observed in more of the parameters. Whereas there were no 
abnormalities observed in H304R/+ mice at 3 months, homozygous mice continue to 
show differences in complexity when compared to wild-type and heterozygotes (Figure 
26B). However, at 6 months the effect of the H304R mutation on NMJ complexity seems 
to be slightly reduced compared to earlier time points. There were significant differences 
in 6 of the complexity parameters compared to 9 parameters at 3 months. Previously in 
H304R/+ mice only surface area to volume ratio was different from normal mice. At 9 
months, the NMJ abnormalities in the homozygous mice are more pronounced, an 
obvious deterioration from the 6-month time point. The defects in NMJ organization are 
most severe at 12 months compared with wild type, with lower values than heterozygous 
(Figure 26E). 
4.2.2.2 H304R/R homozygous mice show abnormalities in innervation 
Innervation defects were consistently recorded in homozygous mice from 1 month to 6 
months, worsening by 9 months and 12 months. Our analysis pointed to denervation in a 
number of homozygous NMJs with negative staining for neurofilament. Even though less 
NMJs are innervated in homozygous mice, we focused on the NMJs with nerves present 
and asked if synaptic activity was normal in these nerves. To ascertain the functionality 
of the neuromuscular synapse beyond the mere presence of neurofilament positive 
staining, we assessed synaptophysin occupancy at the NMJ as a measure of a functioning 
synapse.  
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Figure 27 Synaptic dysfunction in H304R/R homozygous mice 
Representative images of synaptophysin density (red) at each time point in pre-synaptic 
nerves (blue) at the neuromuscular junction of mice. The post-synaptic apparatus is 
stained with alpha–bungarotoxin (green).  
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Synaptophysin is a membrane protein of synaptic vesicles which is widely used as a 
marker for synaptic vesicles (Valtorta et al, 2004). The synaptophysin occupancy is 
obtained from the area of synaptophysin staining divided over the area of AChR staining. 
In heterozygotes, there were no statistically significant differences in synaptic vesicle 
density at early time points, significant differences were observed beginning from 6 
months till 12 months (Figure 25). Although a significant reduction in the number of 
innervated NMJs is not observed in heterozygotes till 9 months, a reduction in synaptic 
vesicle density occurs earlier at 6 months. The density of synaptic vesicles does not 
drastically reduce over time but remains almost constant from 6 to 12 months. In 
H304R/R mice, synaptic vesicle density was consistently lower than wild-type and 
H304R/+ mice, however not all these differences were statistically significant. 
Differences between wild –type and homozygous were significant at all time points 
examined.  
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Figure 28 Synaptic vesicle density at the presynaptic apparatus 
Gastrocnemius muscle sections were stained for synaptophysin and the AChR and 
images acquired via confocal microscopy. Heterozygous mice display deficits in 
synaptophysin density beginning from 6 months, whereas homozygotes show defects 
from the first month up to 12 months. Synaptic vesicle density is expressed as a 
percentage of AChR area and was computed as follows: (synaptophysin area/ AChR 
area) x100. Statistical analysis was carried out using Graph pad and by employing the 
one-way-ANOVA, p<0.05 
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4.2.2.3 Homozygous mice show differences in sub-synaptic nuclei distribution 
Molecular motors are required for the positioning of nuclei in different cell types; and 
mispositioning of nuclei is a hallmark of some muscular disorders. We noticed 
differences in the appearance of nuclei associated with the NMJs between wild-type and 
heterozygous mice. These nuclei looked different in terms of their morphology, and 
arrangement and at times, the number of nuclei also varied between genotypes. After we 
generated homozygous mice with the dynein H304R mutation we continued to notice 
these differences. The nuclei at the neuromuscular junction or sub-synaptic nuclei play 
some distinct roles that sets them apart from the other nuclei in the muscle (Moscoso et 
al, 1995), it is therefore possible they would be targeted as the H304R mutation leads to 
disruptions in NMJ architecture. We proceeded to investigate the differences observed in 
sub-synaptic nuclear arrangement at the NMJ by focusing on the morphology of the 
nuclei and the number present at the synapse. We chose to look first at mice that were 12 
months of age, since we saw a more pronounced neuromuscular dysfunction at this time 
point. We determined the ellipticity of the nuclei to differentiate more oval elongated 
nuclei from more rounded nuclei. The neuromuscular synapse is also infiltrated by nuclei 
from the glial cells which help stabilize the entire apparatus also. Our initial study of 
nuclear morphology and distribution in 12-month-old mice revealed the abundance of 
more elongated nuclei in the muscles of homozygous mice compared to wild type and 
even heterozygotes. The heterozygotes seemed to have more mid-point ellipticity scores 
as seen also in the histogram that quantifies the distribution of these nuclei (Figure 29). 
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Further studies into establishing the identity of nuclei either as myonuclei or glial cell 
nuclei as well as results from other timepoints are ongoing. 
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Figure 29 Distribution of nuclei at the neuromuscular junction 
A) Schematic depicting nuclear morphology at the NMJ from three genotypes (wild-type, 
heterozygous and homozygous) based on confocal images from12 month old mice. The 
area enclosed by the NMJ is marked in yellow as well as the nuclei analyzed. The 
ellipticity scores are shown in boxes and have been color-coded to match the respective 
nuclei. Ellipticity is calculated by dividing the width by the length of the nuclei. B) 
Histogram showing nuclear ellipticity in each genotype as a percent of all nuclei. 
(Number of nuclei analyzed: wild-type=39, H304R/+ =32, H304R/+=34) C) Distribution 
of nuclear ellipticity at the NMJ compared across genotypes. Black bars are wild-type, 
grey bars heterozygotes and dark blue bars homozygotes 
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4.3 Discussion 
4.3.1.1 Changes in NMJ architecture in H304R heterozygous mice 
Based on the motor behavior phenotypes we observed, we decided to examine NMJ 
morphologies in male H304R/+ mice and saw significant differences in NMJ 
morphologies over time (Table 2).  We found that NMJs appeared under-developed at 
one-month of age, with fewer branches, and with those branches having significantly 
longer lengths. However, this phenotype disappeared at 3 months, as the NMJs were 
indistinguishable from control animals at that age. At later time points the NMJs lost 
complexity, and many times appeared to have a larger synapse diameter.  One of the most 
interesting features of the H304R/+ phenotype was the apparent recovery of NMJ 
morphology in young adult mice followed by degeneration as the mice aged.  The defects 
seen at the earliest time point seem to represent a problem in development of the NMJs, 
as less complexity was present.  In contrast, the defects seen in the later time points 
suggests that there may be a separate mechanism in the older animals that is causing 
possible retraction or degeneration at the NMJ during aging.  Future work will be needed 
to test those possibilities. 
 
4.3.1.2 Altered neuromuscular junction morphology in H304R/R animals 
Although CMT disease occurs in humans as an autosomal dominant heterozygous 
mutation, there are some benefits in generating homozygous individuals. From a 
biochemical standpoint isolating components of the mutant dynein complex for further 
analysis is more feasible in a homozygous animal than a heterozygous. This is because 
the population of wild-type or normal dynein that would be present in every isolated 
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fraction is eliminated. Another reason why a homozygous mouse model is exciting is the 
possibility of studying understanding the function or dysfunction of dynein more clearly 
as the protein function is more severely affected compared to the heterozygous model. 
loa/loa homozygous mice die within a day of birth, however studies on the embryos have 
shed more light on the essential functions of dynein in neurons during development 
(Hafezparast et al, 2003, Ori-McKenney and Vallee, 2011). 
Homozygous mice displayed dysmorphology at the NMJ at all time points analyzed, a 
more careful scrutiny of the results point to a lessening of the effects on the NMJ at 6 
months until it increases again from 9 months till the animals are 12 months. Unlike 
heterozygous mice where there is no difference in NMJ complexity at 3 months, the 
H304R/R mice have less severe abnormalities at 6 months. It is possible that the 
heterozygotes are able to overcome some of the relatively milder developmental 
problems by 3 months, but the homozygotes are never able to fully do so since they have 
more severe effects. Even at 6 months when the where there is a diminished effect 
compared to other time points, abnormalities at the NMJ still remain when compared 
with wild type mice. The H304R/R homozygous mouse model is not the first attempt at 
generating a homozygous dynein mouse model, but it is the first to survive up to about 24 
months. The other dynein homozygous mouse models were either embryonic lethal or the 
mice died soon after birth. Therefore, only data from mouse embryos have been studied, 
there is no data on the progression of disease in the adults. This means that with the 
H304R/R homozygous dynein mouse model there is the opportunity to systematically 
investigate disease pathways and obtain purified mutant protein that can be used in 
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various cellular assays to better understand how dynein structure and function is altered 
in a diseased mouse. 
 
4.3.1.3 Nuclear morphology at the Neuromuscular Junction 
Nuclei that are found localized specifically at the NMJ continue to be the subject of much 
interests because of how they contribute to the maintenance of the NMJ and the 
transmission of nerve impulses. An understanding of how they could be affected in 
disease conditions will be important in finding out more about how the entire 
neuromuscular synapse is altered. We conducted an analysis of nuclear morphology in 
wild-type and mutant mice. We observed severe neuromuscular deficits in 12-month-old 
male mice, and so we started by looking at these cohorts. Differences exist in the 
morphology of nuclei in the different genotypes with the wild-type mice having more 
rounded nuclei and less elongated nuclei. There is a shift from a mixture of both rounded 
and oval morphs in heterozygous mice to a predominantly elongated oval nuclei in 
homozygous tissue. This observation could be due to a number of possibilities; the 
presence of more glial cells in the wild type mice compared to the other 2 mutants 
(heterozygotes and homozygotes). It is also possible that the defects in dynein function 
affect the placement of glial cell nuclei during development resulting in a reduction in the 
number of myonuclei. Researchers in an ALS study examined the link between 
denervation and expression of the glial marker, S100 (Carasco et al,2016). They found 
no expression of S100 under conditions of denervation, mice with an ALS mutation 
(SOD1-G93A) are more susceptible to losing the expression of S100 compared to normal 
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mice. This scenario is entirely possible in our study, since we have shown that 
homozygous mice have more denervated NMJs. Further studies would help us establish 
whether a correlation exists between the denervation of the NMJ and reduced expression 
of S100 in a dynein disease model. It will also be important to ascertain whether the 
differences in nuclear distribution and morphology between wild-type and H304R 
mutants (both heterozygous and homozygous) occur at other time points too.  
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CHAPTER 5:CONCLUSION 
5.1 The generation of a novel mouse model to study dynein function 
Dynein function has been widely studied for several years in various systems and that has 
contributed immensely to our understanding of how the motor protein functions within 
cells. The ability to genetically manipulate portions of the dynein-dynactin complex have 
been invaluable in deciphering how its functions are needed in cells. The introduction of 
the three dynein heavy chain mouse models, loa, cra, swl drew the attention of the entire 
field to the critical role dynein plays in neuronal cells. Various studies into these mouse 
models brought to the fore how dynein-mediated retrograde transport may be essential for 
the survival of neuronal cells (Hafezparast et al, 2003). There is therefore a two-fold 
limitation with these mouse models. First, the exact mechanistic pathway through which 
the mutation in the dynein heavy chain gene results in disease is not clear. The other 
limitation is that the loa, cra, swl mutations are not related to a disease in humans, there 
is therefore a bit of a difficulty in relating the findings to humans. We successfully 
generated a knock-in mouse model of CMT2O disease bearing a point mutation (H304R) 
in the dynein heavy chain which corresponds to H306R in humans. Our characterization 
of this mutant mouse revealed a predominant motor phenotype as seen in human CMT2 
disease. This was confirmed through our assays by weakness in the muscle and motor 
coordination defects.  The phenotypic study conducted in loa, cra and swl mice was not 
done in a longitudinal manner and so did not cover all the timepoints in the H304R study. 
However, phenotypic defects in H304R heterozygous mice are milder in comparison to 
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loa, cra, swl mice. The H304R/R homozygous mouse model on the other hand, appears 
to have more robust behavioral characteristics compared to loa,cra, swl heterozygotes. 
The H304R mouse model is therefore a novel and distinct system that can be used to 
study dynein function. The fact that it is linked to a disease in humans addresses the issue 
of relevance in the search for therapeutics and makes it suitable for translational research. 
5.2 Connecting the dots between dynein mutations and neurological disorders 
The ultimate goal of our study is to understand dynein function better, and in the specific 
case of our H304R mouse model, we hope to achieve this aim by following the onset and 
progression of CMT2O disease, caused by a mutation in the dynein heavy chain gene. 
We have shown that the neuromuscular junction is a pathological target in CMT2O 
disease (Sabblah et al, 2018). The abnormalities in the NMJ are obvious in both 
heterozygous and homozygous models, with the deformities worsening in the 
homozygotes. There is still more work required to arrive at a mechanism for CMT 
disease in our H304R mouse model. A legitimate question that arises is how does dynein 
function affect NMJ architecture?  It is known that dynein transport of essential cargoes 
in axons towards the nucleus is important in many neuronal processes (Levy and 
Holzbaur, 2006). We can therefore hypothesize that NMJ defects in H304R mouse 
models are partly due to dynein dysfunction in the motor neurons that innervate the axon. 
There is evidence of that in our study where we saw reduced innervation and a 
concomitant increase in NMJ dysmorphology at later stages in heterozygous mice. 
Dynein activity in the muscle could also be a contributory factor. It was discovered that 
disrupting dynein function alters the components of the neuromuscular synapse in 
primary myoblasts from mice (Vilmont et al, 2016). Our initial analysis of subsynaptic 
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nuclei at the NMJ suggests a difference in the distribution and morphology of nuclei in 
mutants compared to wild-type. This could be another pathway that disrupts the NMJ 
organization in H304R mutant mice since dynein is an essential player in myonuclear 
positioning (Folker et al, 2014).   
We cannot rule out the possibility of a structural defect in the dynein protein itself or a 
change in interaction with its binding partners. The dynein motor protein is a massive 1.6 
MDa complex made up of four kinds of subunits that need to be present in the right 
stoichiometric proportions to be assembled into a functional unit. In addition to that, the 
dynein complex interacts with other key adaptors and regulators like dynactin, BicD, Lis1 
that are required for complete function in cells. A mutation in any of the dynein subunits 
could possibly affect how the subunits interact or how other accessory proteins interact 
with dynein and ultimately alter dynein function to cause disease. Interestingly, a study 
involving 14 DYNC1H1 heavy chain mutations, did not find any change in the 
association of dynein with dynactin-BICDN complexes in majority of the human 
mutations, including the H306R mutation (Hoang et al, 2017). With that being said, it 
will be interesting to know what the dynein subunit levels are in the H304R homozygous 
mutant as well, and what kind of outcomes will be obtained from single-molecule assays 
using only a homogenous population of mutant protein. 
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Figure 30 Severity of phenotypes continuum 
Comparison of the severity of mouse DHC mutations with the CMT2O DHC phenotypes 
observed in human patients. Heterozygous mouse H304R/+ phenotypes are similar to 
those of H306R/+ CMT2O patients. Heterozygous mouse loa/+, cra/+, swl/+ phenotypes 
are more severe than those of H304R/+ mice. Homozygous H304R/R phenotypes are 
more severe than loa/+, cra/+, swl/+ phenotypes. Homozygous loa/loa, cra/cra, swl/swl 
phenotypes are the most severe resulting in death. 
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5.3 So how does the H304R mutation cause disease? 
Studies in N. crassa involving the expression of various dynein heavy chain mutations 
resulted in 5 different classes of phenotypes based on the localization of cytoplasmic 
dynein in the hyphae (Sivagurunathan et al, 2012). What this study taught us is that 
phenotypes generated from dynein heavy chain mutations are heterogeneous. Pleiotropic 
manifestations are observed in the different human mutations as well. The majority of the 
dynein heavy chain (DHC) mutations are described as SMA-LED (spinal muscular 
atrophy with a lower extremity predominance based on their features in patients. The 
SMA-LED phenotype is mainly characterized by lower muscle atrophy and weakness. 
There were other neurological defects in humans with mutations in the dynein heavy 
chain gene. Some patients with the H306R mutation which causes CMT2O disease had 
pes cavus and an abnormal gait. Less common manifestations of the disease include 
impaired speech and learning difficulties (Weedon et al, 2011). Intellectual disorders 
have also been reported in other dynein heavy chain mutations (Strickland et al, 2015, 
Scoto et al 2015). Malformations of cortical defects were observed in some dynein heavy 
chain mutations as well (Poirier et al,2013). Even though there are over 20 dynein heavy 
chain mutations discovered in humans, there isn’t a lot known about the prevalence for 
any one individual mutation or all of the DHC mutations. The first publication about 
dynein heavy chain mutations in humans came out about 7 years ago, which makes it 
quite a short period of time to have volumes of data to compute prevalence rates. Perhaps 
epidemiological data will become available after a while when more cases are reported. 
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The point to note is that the heterogeneity of the disease manifestations could be strongly 
linked to the mechanism of the disease. In simple terms, multiple manifestations could be 
due to multiple disease pathways. Another significant observation regarding the 
phenotypes of DHC mutations is the variation in severity. Differences in the extent of the 
disease manifestation could occur within a cohort, varying from individual to individual, 
as previously reported in human patients (Weedon et al, 2011, Scoto et al, 2015). We 
however wanted to capture any differences that might exist among different DHC 
mutations. By comparing our H304R mouse model with other dynein mouse models 
namely loa, cra and swl, we noticed differences in how the mice are affected by 
mutations in the DHC gene (Figure 30). We are unable to determine which of the other 
DHC human mutations would correspond to those of the mouse DHC genes since there 
are no mouse models for those other human mutations.  
Beyond the motor phenotype observed in the behavioral assays, we were interested in 
uncovering dynein related functions that could be contributors to CMT disease in the 
H304R mutant mice. Neuromuscular junction defects have already been reported in 
dynein and CMT2 mouse models (d'Ydewalle et al, 2011, Sleigh et al, 2014, Spaulding et 
al, 2016, Courchesne et al, 2011). NMJ analysis in the dynein H304R mutant mice also 
unveiled dysmorphology and reduced complexity which were even worse in the 
homozygous mice. 
To probe dynein dysfunction even further, it is important to consider the tripartite 
components of the neuromuscular apparatus, namely the motor nerves, the muscle fiber 
and the terminal Schwann cells. Dynein function has been studied in the motor and 
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neuron and in muscles but not much is known about dynein function in Schwann cells 
especially the terminal Schwann cells that cap the neuromuscular junction. We observed 
innervation defects in H304R mice, pointing to possible defects in dynein-mediated 
transport in the axons. The dynein complex transports cargo from the synaptic end of the 
axon to the soma, some of these include, molecules marked for degradation, recycling 
endosomes and ribonucleoproteins. Dynein dysfunction could lead to a reduction in 
transport efficiency and may even impact kinesin-mediated anterograde transport. This 
could be a very important factor in the development of disease because some cargo are 
transported in both anterograde and retrograde directions (Brady et al, 1990, Hendricks et 
al, 2010).  
This could partially explain why the perturbation of dynein function via a point mutation 
in the heavy chain gene for instance, will result in defects in neuromuscular abnormalities 
in an organism. Knock out studies done in mice have shown that without dynein, mice 
die art the embryonic stage (Harada et al,1998). As such we expect that mice that survive 
with a dynein mutation would not have a complete loss of dynein function.  Additionally, 
the fact that H304R mutant mice are ambulatory means there may not be a grave 
malfunction such as the inability to transport cargo but rather an alteration of dynein 
function leading to a delay in the delivery of some kind of cargo sounds more likely. The 
slight change in dynein function is probably the reason why CMT2O patients have a 
slowly progressing motor and sensory neuropathy. In these patients also, the onset is 
variable and so is the phenotype of the disease. Motor neurons may be vulnerable to 
dynein mutations by their length, which represents a large distance over which cargo has 
to be transported. Most of the proteins required by neurons are synthesized in the soma 
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and must therefore be delivered to the various compartments where they are needed. This 
makes axonal transport indispensable to neuronal survival. The defective axonal transport 
model is a likely mechanism in the H304R dynein heavy chain gene mutation that causes 
CMT2O disease.  
Work done in cultured muscle cells showed a direct involvement of dynein in the 
organization of the post-synaptic apparatus. The inhibition of dynein function led to 
aberrations in the trafficking of the muscle specific kinase (MuSK), which helps cluster 
the receptors and maintain the structural cohesion of post-synaptic components (Vilmont 
et al, 2016). The possibility of MuSK transport being a key driver of NMJ 
dysmorphology in H304R mutant mice would require further studies using cells from the 
muscles of mice. Such an investigation at the cellular level will enable us to assess other 
dynein functions like the maintenance of Golgi and microtubule integrity. Dynein 
functions in muscle development although myosin is the molecular motor required for 
contraction in the muscle. Dynein is involved in the movement and placement of 
myonuclei, which is very critical in muscle function. As muscle cells are syncytial, the 
positioning of nuclei occurs at defined intervals to create sectors of transcriptional control 
for each nucleus (Bruusgard et al, 2003). Live cell experiments in the fruit fly show 
dynein is needed to properly position myonuclei (Folker et al, 2014). A similar 
mechanism may be needed to cluster nuclei at the synaptic region that are in close 
proximity to the AChR in the muscle. Preliminary results from our lab suggest a 
difference in nuclear distribution in the synaptic region (Figure 29).  The synaptic nuclei 
also contribute to the AChR pool that is clustered to ensure efficient communication from 
the nerves (Ferraro et al, 2012). This means that changes in the organization of sub-
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synaptic nuclei arising from the H304R mutation could be a factor in the reduced 
complexity observed in mutant NMJs. 
There isn’t much information about dynein function in glial cells. Dynein is known to 
play a role in myelination in zebrafish via its involvement in the expression of some vital 
genes (Yang et al, 2015). Work done in oligodendrocytes of zebra fish specifically 
identified myelin basic protein (MBP) as a cargo transported by the dynein/dynactin 
complex, and disrupting this complex reduces the expression of MBP, which is required 
to maintain myelin stability (Herbert et al, 2017). Without much evidence specifically 
linking cytoplasmic dynein function to terminal Schwann cells, the scenario where 
dynein influences the expression of vital genes in the terminal Schwann cells still remains 
a possibility that has to be adequately tested. The ubiquity of dynein and its multifarious 
roles in living organisms reflects in the mechanisms of diseases that result from DHC 
mutations. In H304R mutant mice it is likely that a combination of altered dynein 
transport defects in the motor neuron, defective trafficking of one or more synaptic 
components and dysfunction in glial cells at the neuromuscular junction contribute to the 
predominant motor defects observed in mutant mice. 
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ABSTRACT 
Charcot Marie Tooth disease (CMT) represents the most common inheritable peripheral 
group of motor and sensory disorders; affecting 1 in 2500 people worldwide. Individuals 
with CMT experience slow progressing weakness of the muscle, atrophy, mild loss of 
motor coordination and in some cases loss of sensory function in the hands and feet 
which could ultimately affect mobility. Dynein is an essential molecular motor that 
functions to transport cargos in all cells. A point mutation in the dynein heavy chain was 
discovered to cause CMT disease in humans, specifically CMT type 2O. We generated a 
knock-in mouse model bearing the same mutation(H304R) in the dynein heavy chain to 
study the disease. We utilized behavioral assays to determine whether our mutant mice 
had a phenotype linked to CMT disease. The mutant mice had motor coordination defects 
and reduced muscle strength compared to normal mice. To better understand the disease 
pathway, we obtained homozygous mutants from a heterozygous cross, and the 
homozygotes show even more severe deficits compared to heterozygotes. They also 
developed an abnormal gait which separates them from heterozygous mice. In view of the 
locomotor deficits observed in mutants, we examined the neuromuscular junction (NMJ) 
for possible impairments. We identified defects in innervation at the later stages of the 
study and abnormal NMJ architecture in the muscle as well. The dysmorphology of the 
NMJ was again worse in the homozygous mutants with reduced complexity and 
denervation at all the timepoints assessed. Our homozygous dynein mutants can live up to 
two years and therefore make the design of longitudinal studies possible. Altogether, this 
mouse model provides dynein researchers an opportunity to work towards establishing 
the link between dynein mutations, dynein dysfunction and the onset and progression of 
disease. 
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